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Abstract
Induction of anesthesia is often associated with hemodynamic instability. Patients
undergoing cardiac surgical procedures are at a heightened risk of morbidity and
mortality due to weakened heart function and thus hemodynamic stability is of paramount
importance. Anesthesia providers often base clinical decisions on personal preference
rather than evidence-based factors. Decision trees can provide a reference tool to guide
evidence-based decision-making. The purpose of this paper was to propose a
preliminary, evidence-based decision tree to guide in the selection of an appropriate
intravenous anesthetic for patients undergoing cardiac surgery. Information Processing
Theory and PRISMA were used as frameworks to guide the research process and creation
of the decision tree. Nine randomized controlled trials published in the last ten years
were identified and relevant data were extracted and organized into data tables. Quality of
the studies were evaluated utilizing the CASP method and PRISMA. A cross-study
analysis was performed to identify common findings across studies. Recommendations
for appropriate interventions at decision points were developed from the cross-study
analysis. Advanced Practice Registered Nurses are uniquely qualified to integrate
evidence-based decision-making tools into everyday clinical practice. Nursing education
and nursing practice emphasize using the most current evidence to guide patient care.
Certified Registered Nurse Anesthetists are looked upon to demonstrate leadership within
their organizational structures to identify areas for improvement, seek out evidence to
guide change, and implement that change within their sphere of influence and beyond.
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Creation of a Preliminary Evidence-Based Decision Tree for Selecting an Intravenous
Anesthetic for Cardiac Surgery
Background/Statement of the Problem
During induction of anesthesia, a patient is taken from the pre-procedure state of
consciousness to a state characterized by lack of consciousness, awareness, and reflexes.
During this process, patients lose nearly all physiologic self-protection mechanisms. It’s
incumbent upon anesthesia providers to utilize the best options available to execute an
induction with the least chance of negative effects for the patient. While multiple options
are available to facilitate induction, the use of intravenous anesthetic medications is the
most typical technique used with adult patients (Dean & Chapman, 2018). Despite the
risks involved and availability of information, anesthesia providers often select particular
medications based on factors unrelated to individualized patient needs or best practices
(Munst, Schlapfer, & Biro, 2018).
Propofol, etomidate, and ketamine are the most commonly used intravenous
anesthetics in the United States today. Each of these medications possesses distinct
mechanisms of action, durations of action, side effects, and risks associated with their
use. This information is a component of basic education in anesthetic pharmacology.
Clinical training reinforces classroom work by providing opportunities during which
student anesthesia providers witness the effects and patient responses to these
medications and respond accordingly under the supervision of more experienced
colleagues. Patients undergoing cardiac surgery are at much greater risk for
complications due to underlying cardiac disease and lack of physiologic reserve
(Contrera, Patterson, & Cushing, 2014). It’s imperative that the anesthesia provider
ensure a safe induction for patients and specifically for those undergoing cardiac surgery.
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Each anesthetic involves numerous instances where the anesthesia provider must
choose a suitable intervention in response to an occurrence. Despite years of training and
common basic understanding, large variations in practice and decision-making continue
to cause delays and errors in treatment, many of which result in patient harm (Stiegler &
Tung, 2014). Decision-making aids, clinical pathways, and algorithms have been
developed in most healthcare disciplines to provide practitioners with evidence-based
tools to assist in selecting the most appropriate intervention in a given situation. Properly
tailored, created, and implemented, these tools have been shown to significantly reduce
morbidity and mortality (Rotter et al., 2012).
The purpose of this paper was to propose a preliminary, evidence-based decision
tree to guide in the selection of an appropriate intravenous anesthetic for patients
undergoing cardiac surgery.
Next, the review of the literature will be presented.
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Literature Review
A literature review was performed utilizing the research databases Academic
Search Complete, CINAHL Plus with Full Text, and MEDLINE. Search terms included
induction of anesthesia, intravenous induction agents, propofol, etomidate, ketamine,
cardiac surgery, coronary artery bypass graft, valvular disease, decision making, and
decision tree, which were searched individually and in combination. The search was
limited to articles published in the last ten years. Reference sections of located articles
were also mined for additional applicable articles.
Induction of Anesthesia
General anesthesia is a state in which a patient is pharmacologically rendered
completely unconscious and unresponsive to all external stimuli (American Society of
Anesthesiologists [ASA], 2014). Under general anesthesia, patients are unable to
independently support their own airway patency and ventilatory status and often require
assistance to preserve cardiac and vascular function. The induction phase is the portion
of the anesthesia process during which the patient is taken from his/her pre-anesthetic
state to a state of general anesthesia (Nagelhout, 2014). Induction of general anesthesia is
carried out with the administration of either inhalation anesthetics or intravenous
anesthetics.
Inhalation Induction. The first use of inhalation anesthetics can be traced to the
mid-1800s, during which the use of ether, chloroform, and nitrous oxide became common
methods used to induce and maintain general anesthesia (Khan, Hayes, & Buggy, 2014a).
The effects of inhalational anesthetics were once thought to be directly related to their
chemical property of solubility in lipids, with those agents expressing a greater degree of
lipid solubility exhibiting greater potency. Further research has discovered that the
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effects of inhalational anesthetics are far more nuanced, with differing mechanisms in the
spinal cord, above the spinal cord in the brain, at ion channels and nerve synapses, and
upon particular protein subunits at the molecular level. Movement into, through, and out
of the body is primarily related to the lipid solubility of the inhalation anesthetic, but also
affected by the particular patient’s cardiovascular status, ventilatory function, and amount
of adipose tissue (Khan et al.).
Inhalational anesthetics are not without their risks and side effects. For example,
two of the commonly available agents, isoflurane and desflurane, are quite pungent and
cause airway irritation and coughing, which is troublesome for patients with reactive
airway disease (Kossick, 2014). Inhalation anesthetics cause systemic vasodilation
leading to decreases in mean arterial pressure (MAP) and cardiac output (CO) and can
generate arrhythmias. All of the volatile inhalation anesthetics are potent triggers of
malignant hyperthermia, which is an anesthetic emergency and can lead to fatal
elevations in body temperature (Kossick).
Inhalation induction is accomplished with the exclusive administration of one of
the volatile anesthetic gases (Dean & Chapman, 2018). A mask is placed over the face
and the patient inhales larger concentrations of an inhalation anesthetic than would be
normally used for the maintenance phase. Inhalation induction is commonly employed
with pediatric patients, who are more likely to express fear of needles. Inhalation
anesthetics result in a longer induction time and increase the risk of laryngospasm. With
the exception of children and those patients with severe aversion to needles, inhalation
induction has been replaced with intravenous induction in the overwhelming majority of
cases (Dean & Chapman).
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Intravenous Induction. Similar to inhalation induction, intravenous induction is
the process by which patients are transitioned to a state of general anesthesia utilizing
medications that are administered intravenously rather than into the lungs. Intravenous
induction produces a faster transition from consciousness to general anesthesia than the
inhalational method (Nagelhout, 2014). Intravenous induction also produces a smoother
process, which is generally more enjoyable for the patient. Intravenous anesthetics are
not known to generate laryngospasm and produce a rapid, controlled induction process
that can be tailored to the specific physiologic demands of each individual (Nagelhout).
Rapid sequence induction (RSI) is a modified form of intravenous induction whereby an
intravenous anesthetic is administered, immediately followed by a neuromuscular
blocking agent to render the patient immediately unconscious and immobile to facilitate
airway management in patients at greater risk of aspirating stomach contents (Dean &
Chapman, 2018).
Intravenous Anesthetics
Thiopental entered common use in the early 1930s and is generally considered the
first intravenous anesthetic (Khan, Hayes, & Buggy, 2014b). A myriad of intravenous
anesthetics have been developed since, although only four agents, propofol, etomidate,
ketamine, and thiopentone, are in general use (Dean & Chapman, 2018). Thiopentone
was removed from the United States market in 2011, leaving propofol, etomidate and
ketamine as the intravenous anesthetics most commonly used today (Nagelhout, 2014).
Propofol. First patented in 1977 by Roger James and John Glen, propofol was
introduced in the United States as an intravenous anesthetic in 1989 (Sahinovic, Struys,
& Absalom, 2018). It is only soluble in lipid-based emulsions and is formulated to
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include glycerol, soybean oil, and egg lecithin (Sahinovic et al). Despite this
formulation, propofol has been shown to be safe for use in patients with known allergies
to eggs and soy (Harper, 2016). Initially, propofol was found to have a propensity for
harboring bacteria and easily becoming contaminated (Sahinovic et al.). This problem
was rectified by the addition of ethylenediaminetetracetic acid (EDTA), which was added
as a preservative to decrease the incidence of contamination (Sahinovic et al.). Many
generic forms of propofol, especially those manufactured outside the United States,
utilize other preservatives including sodium metabisulfite (Nagelhout, 2014). This is
problematic for patients with known sulfite allergies. Name brand propofol, marketed as
Diprivan © in the United States, is only available with the EDTA preservative
(Nagelhout). Facilities that use generic formulations should keep a small cache of
EDTA-preserved propofol on hand for use in patients with sulfite allergies.
Notwithstanding the presence of the preservative, it is generally accepted practice to
discard any propofol that was removed from its original vial within six hours of doing so
and to discard any container that has been accessed within 12 hours of opening
(Nagelhout).
Pharmacologically, propofol is characterized by a rapid onset due to its high lipid
solubility (Sahinovic et al., 2018). The speed with which molecules cross lipid
membranes is directly related to the lipid solubility characteristics of the molecule. As
such, propofol easily crosses the blood-brain barrier (BBB), rapidly inducing a state of
general anesthesia. Lipid soluble molecules can cross lipid membranes in both
directions. Rapid redistribution of propofol from the brain back into the bloodstream
accounts for the relatively fast wake-up time after a bolus dose. Once back in the blood-
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stream, propofol molecules will deposit into other areas where lipid membranes exist,
such as adipose tissue (Sahinovic et al.). Although the therapeutic effects of propofol
will not generally be observed after redistribution, the body must still metabolize it before
it is eliminated from the body. The speed with which this occurs is dependent upon the
blood supply to the areas in which the molecules were deposited. If propofol is
administered as an infusion, the duration of the infusion will determine the extent to
which molecules are deposited in other areas of the body. Termed the context-sensitive
half time, the duration of time necessary for the plasma concentration of propofol to be
reduced by 50% after stopping the infusion will be longer for infusions of greater
duration and in patients with a large amount of adipose tissue (Sahinovic et al.).
Propofol acts upon the γ–amino butyric acid receptor (GABAA) in the central
nervous system (CNS) (Nagelhout, 2014). The ligand for that receptor, γ–amino butyric
acid (GABA), is one of the most important neurotransmitters in the CNS for inhibiting
neuronal activity. Upon binding of GABA to GABAA, ligand-gated chloride channels
open and facilitate the movement of ions, altering membrane potential. The altered
membrane potential inhibits depolarization of the neuron, decreasing its activity.
Propofol does not directly bind to GABAA. It stimulates the receptor to bind to the
patient’s own GABA and elicit the response (Nagelhout).
Upon administration and onset of a dose of propofol, a number of normal
physiologic mechanisms are depressed (Khan et al., 2014b). Administration is followed
by rapid loss of consciousness. Propofol constricts cerebral blood vessels, leading to a
decrease in cerebral blood flow (Nagelhout, 2014). This decrease contributes to a
lowering of intracranial pressure. Depression of neuronal activity reduces the cerebral
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metabolic rate of oxygen consumption (CMRO2) (Nagelhout). Neuronal depression
additionally contributes to propofol’s ability to act as an anticonvulsant and antiemetic
(Sahinovic et al., 2018). Propofol also exhibits substantial cardiorespiratory changes. It
is a direct suppressant of myocardial activity and vascular tone. As a result, myocardial
inotropy, arterial vasoconstriction and venous return are all reduced. Profound
hypotension and reflex tachycardia can occur. In induction doses, propofol produces
apnea, loss of gag reflex, and loss of muscle control of the larynx, which are helpful
during airway management (Sahinovic et al.). Direct intravenous injection of propofol
can cause irritation of the local blood vessel and pain with injection (Nagelhout, 2014).
Awakening after a dose of propofol is based upon the medication leaving the CNS
and is virtually unaffected by metabolism of the drug (Nagelhout, 2014). The liver
quickly performs phase I metabolism via the cytochrome P450 system, with metabolites
being conjugated during phase II metabolism by glucuronic acid; the metabolites are
pharmacologically inactive (Sahinovic et al., 2018). The demonstrated rate of
metabolism is in excess of hepatic blood flow. Propofol metabolism has also been
demonstrated in the kidneys, small intestines, and lungs. Greater than 99% of a dose of
propofol is excreted after metabolism, with a fractional amount excreted in its native
chemical structure. The vast majority of the metabolites are excreted by the renal system,
although small amounts are excreted through the lungs upon exhalation. In some
patients, after prolonged exposure to propofol infusions, some of the metabolites can
discolor the patient’s urine bluish-green (Sahinovic et al.).
Etomidate. Etomidate was initially created in the mid 1960’s and became
commonplace in clinical practice in the early 1970’s (Nagelhout, 2014). It was originally
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utilized for treating fungal infections prior to the discovery of its anesthetic capabilities
(Forman, 2011). Etomidate’s chemical structure expresses chirality, with two possible
enantiomers. Refined preparations of the R(+)-enantiomer have been shown to be
significantly safer than a racemic mixture. Commercially available etomidate is supplied
as the pure R(+)-enantiomer (Forman).
Etomidate’s effects are mediated by the GABAA receptor (Forman, 2011).
Etomidate increases GABA’s affinity for GABAA by binding to a specific location within
the GABAA receptor (Rathmell & Rosow, 2015). Etomidate’s pharmacokinetic profile is
similar to propofol. Rapid unconsciousness is realized due to etomidate’s high lipid
solubility and propensity for crossing the BBB (Nagelhout, 2014). Its action upon
GABAA receptors stimulates the opening of ligand-gated ion channels, inhibiting
neuronal activity. Short duration of action is related to redistribution out of the CNS.
Metabolism occurs via the cytochrome P450 system to water soluble substances
(Nagelhout). All but a small fraction of the metabolites, which have no pharmacologic
function, are excreted in the urine, with the remainder removed from the body through
the GI tract as a component of bile (Rathmell & Rosow, 2015).
Etomidate produces a rather unique pharmacodynamic response. Etomidate
causes a constriction of cerebral blood vessels, which produces a reduction in CMRO2
and intracranial pressure (ICP) (Nagelhout, 2014). Cerebral perfusion pressure is
maintained. When administered as a component of the anesthesia regimen for
electroconvulsive therapy (ECT), etomidate prolongs the neurologic seizure activity seen
on electroencephalogram (EEG) (Nagelhout). Routine administration to patients with a
known history of epilepsy should be avoided (Rathmell & Rosow, 2015). Although

10

etomidate has shown to prolong seizure activity during ECT, it has also been shown to
provide some action as an anticonvulsant and has been used successfully during the
treatment of status epilepticus. Etomidate is known for its stable cardiovascular response.
Stroke volume (SV), heart rate (HR), and cardiac output (CO) are maintained, while a
slight decrease in systemic vascular resistance (SVR) may occur. Etomidate’s stable
cardiovascular profile has led to its common use in patients with depressed heart
function, severe trauma, and other clinical situations involving hemodynamically
compromised patients. Etomidate has been demonstrated to depress myocardial
contractility; however, quantities needed to elicit this response far exceed the therapeutic
dose (Rathmell & Rosow). The baroreceptor reflex and sympathetic tone are maintained
(Nagelhout, 2014). Arrhythmias of any clinical significance are rare. Patients carrying
diagnoses of mitral or aortic valve pathologies may experience acute hypotension after
receiving Etomidate. With the exception of a possible transitory period of apnea after the
administration of an induction dose, respiratory rate is maintained. Histamine is not
released in response to administration and there is no effect on bronchial smooth muscle
(Nagelhout).
Etomidate produces some adverse effects that must be weighed against its
benefits and may limit use in certain patients. The most significant adverse effect of
etomidate is its inhibition of steroid synthesis by the adrenal glands (Erdoes, Basciani, &
Eberle, 2014). Etomidate is a potent inhibitor of 11 β-hydroxylase, a microsomal enzyme
of the cytochrome P450 system, which is responsible for a critical step in the cascade of
reactions that produces cortisol. Adrenal inhibition is greater than the anesthetic effect
for a given dose and can continue for 24-72 hours in some patients. This has resulted in
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the discontinuation of etomidate for long-term intravenous infusions in critically ill
patients (Erdoes et al.). Mixed results from several randomized studies have created
controversy about its use in bolus doses in patients for whom a depressed adrenal stress
response could prove detrimental (Nagelhout, 2014). Studies examining the efficacy of
supplementing affected patients with exogenous steroids have also demonstrated mixed
results (Nagelhout). Etomidate also causes myoclonus, which is an episode of
involuntary muscle contractions sometimes misinterpreted as seizure activity. This is
thought to be a result of disparate timing of action in certain parts of the brain, during
which inhibitory neurons are anesthetized prior to excitatory neurons, resulting in
overexcitation of the excitatory pathways (Nagelhout). This usually has little clinical
significance, as etomidate is routinely accompanied by medications that produce
neuromuscular blockade and skeletal paralysis. Patients experience pain at the site of
injection and etomidate has been directly linked to post-operative nausea and vomiting
(PONV) (Forman, 2011).
Another important physiologic effect that must be considered is the relationship
of etomidate to the condition porphyria. Porphyrias are genetically inherited or acquired
metabolic disorders resulting in a decreased supply of an enzyme required to synthesize
heme, a foundational component of the hemoglobin molecule (Nagelhout, 2014).
Porphyrins are chemical precursors to heme, which can cause neurologic damage if they
accumulate in high doses. Etomidate is an inducer of the enzyme ALA-synthetase, the
enzyme that catalyzes as the rate-limiting step in the cascade of reactions that produce
heme. Induction of ALA-synthetase increases the rate of production of porphyrins. The
patient with a porphyria cannot maintain a heme production rate equivalent to the rate of
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porphyrin production, causing them to accumulate. Etomidate is contraindicated in
patients with a recognized porphyria (Nagelhout).
Ketamine. Various sources report the first use of ketamine in the clinical setting
sometime in the mid-1960s to early 1970s (Khan et al., 2014b; Nagelhout, 2014).
Ketamine is a hydrophilic molecule that contains a single chiral carbon, with two possible
enantiomers (Rathmell & Rosow, 2015). The racemic mixture of both enantiomers is the
primary formulation that is commercially available. A pure formulation of the S(+)enantiomer exists but is not in common use. S(+)-ketamine was found to offer superior
desired effects with fewer untoward reactions (Rathmell & Rosow). S(+)-ketamine has
been found to offer only trivial clinical benefits that don’t justify the costs associated with
isolating the pure preparation (Nagelhout, 2014).
Ketamine’s mechanism of action is substantially dissimilar to that of propofol or
etomidate (Nagelhout, 2014). The primary site of action is at the N-methyl-D-aspartate
(NMDA) receptor, although it has been shown to display effects at other receptors as
well, including adenosine, cholinergic, monoamine, opioid, and purinergic receptors.
Ketamine also alters gene expression of interleukin-6 (IL-6) and tumor necrosis factoralpha (TNF-α), providing some anti-inflammatory effects. Ketamine can also be used for
its direct analgesic properties, whereby it blocks the transmission of pain in the dorsal
horn of the spinal cord (Nagelhout). Ketamine’s actions at the GABAA receptor is
negligible (Rathmell & Rosow, 2015). One of Ketamine’s main benefits is its
compatibility with multiple routes of administration in addition to the intravenous route.
It can be administered via the intraosseous, intramuscular, intranasal, and oral routes; a
Ketamine lozenge is also available (Marland et al., 2013).
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Ketamine’s high lipid solubility leads to it easily crossing the BBB, leading to
rapid unconsciousness, followed by redistribution out of the CNS leading to a short
duration of action (Rathmell & Rosow, 2015). Metabolism is carried out by the
cytochrome P450 system in the liver. The principal metabolite of ketamine is
norketamine, which has active pharmacologic effects, prolonging the effects at receptors
outside the CNS. Phase II metabolism conjugates norketamine into an inactive
hydrophilic compound, promoting renal elimination. Ketamine serves to induce the
cytochrome p450 enzymes responsible for its metabolism, accelerating its elimination
half-life over time. Tolerance can develop with prolonged use (Rathmell & Rosow).
Ketamine produces a wide array of pharmacodynamic effects. Intravenous
administration of an induction dose creates a state of dissociative anesthesia, whereby the
patient enters a catatonic state (Nagelhout, 2014). The patient does not interact with the
environment but may appear awake. Central nervous system reflexes, including corneal
and pupillary reflexes, are maintained. A cardinal sign of Ketamine administration is
nystagmus. Patients can sneeze, cough, and swallow, while maintaining airway
protective reflexes. Ketamine administration is accompanied by increased oral
secretions, which increases the possibility of laryngospasm in the setting of preserved
airway reflexes. Ketamine dilates cerebral blood vessels, leading to an increase in
cerebral blood flow (CBF), CMRO2 and ICP. Ketamine is generally avoided in patients
at risk for increased ICP (Nagelhout).
Ketamine’s desirability in critically ill patients is related to its cardiovascular
effects. Ketamine causes sympathetic stimulation of the myocardium, resulting in
increases in HR, CO, and SVR (Rathmell & Rosow, 2015). Myocardial workload
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intensifies, which increases myocardial oxygen demand. Blood pressure (BP) in the
pulmonary circuit and system circuit are augmented. Serum lactate levels may increase
(Rathmell & Rosow). A different medication should be chosen for patients who struggle
to control their BP, or for those with a known history of ischemic heart disease (Khan et
al., 2014b). Ketamine is not a catecholamine, so does not directly stimulate adrenergic
receptors in the heart or blood vessels (Rathmell & Rosow, 2015). Ketamine’s
sympathomimetic effects are likely derived from the stimulation of endogenous
catecholamines or interfering with their reuptake. Patients suffering from catecholamine
depletion have demonstrated cardiac depression after receiving ketamine. Respiratory
depression is insignificant, other than transient apnea following swift administration of an
induction dose. Ketamine causes bronchodilation and is considered the most desirable IV
induction agent for patients experiencing symptomatic reactive airway disease (Rathmell
& Rosow). Several international organizations have published recommendations that
include ketamine as the first or only choice of IV anesthetic in emergency situations,
trauma, and in developing countries (Morris, Perris, Klein, & Mahoney, 2009).
Adverse reactions limit the use of ketamine in certain situations. Emergence
delirium, with concomitant auditory and visual hallucinations, temporary blindness and
vivid dreams, commonly occurs (Rathmell & Rosow, 2015). Acute schizophrenia and
other psychotic symptoms have been reported (Marland et al., 2013). Ketamine has been
shown to lower the incidence cognitive dysfunction in patients undergoing cardiothoracic
surgical procedures (Hudetz et al., 2009). The safety of ketamine in patients with
porphyrias is controversial; use should be reserved for situations in which the benefits far
outweigh the risks (James & Hift, 2000).
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Anesthesia Induction for Cardiac Surgery
Cardiac surgery can present a challenging set of circumstances for the anesthesia
provider. Patients often come to surgery with a myriad of coexisting diseases, while
cardiovascular status has deteriorated to the point that surgical correction is required.
Tight control of hemodynamic stability is essential while accounting for existing
comorbidities and pharmacologic side effects (Mittnacht, London, Puskas, & Kaplan,
2018). Selection of the appropriate IV anesthetic will be guided by the pathophysiology
of the particular cardiac condition for which the patient requires repair.
Valvular Disease. Blood travels through a valve as it exits each chamber of the
heart. Properly functioning, valves prevent retrograde blood flow while permitting
unimpeded antegrade flow, generating a predictable pressure/volume relationship in each
chamber (Contrera et al., 2014). While disease in the valves of the left heart are
common, valve disease in the right heart is considerably less likely (Contrera et al.).
Cardiovascular sequelae from valve disease can include structural changes such as
hypertrophy, arrhythmias, and frank cardiac failure (Herrera, 2018). Diseased valves can
either fail close properly (regurgitation) or fail to open completely (stenosis). The
structural changes and symptomatology differ according to valve and pathology.
Anesthesia providers must choose the appropriate medications based upon the particular
valve involved, the type and severity of the valve condition, and the cardiovascular
pharmacodynamics of the particular drug (Herrera).
Aortic Stenosis. The most commonly occurring valve disease in the
industrialized world, aortic stenosis is a condition in which the aortic valve is unable to
open completely (Contrera et al., 2014). While usually a result of calcification of the
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valve, a small segment of the population is born with a bicuspid valve (a normal valve
has three cusps), which is more likely to stenose (Herrera, 2018). Patients with a
bicuspid valve develop symptoms earlier in life and often require surgical correction at a
younger age (Herrera).
In response to the decreased movement of blood into the systemic circulation, the
heart compensates by generating more pressure in the left ventricle to maintain cardiac
output (Herrera, 2018). The structural response is consistent with increased workload by
any muscle group, in that it stiffens and hypertrophies. The hypertrophied left ventricle
balances the strength of contraction with the degree of stenosis to maintain a pressure
gradient on either side of the valve. The additional workload on the heart muscle
substantially increases oxygen demand (Herrera). The hypertrophied ventricle cannot
relax appropriately, leading to diastolic heart failure (Paul & Des, 2017).
Anesthetic management of aortic stenosis involves maintaining the pressure
gradient between the left ventricle and the aorta (Contrera et al., 2014). Emphasis must
be placed on preserving adequate preload, maintenance of synchrony between the atria
and ventricles, assuring sufficient time for ventricular filling, and preventing abrupt
reductions in systemic blood pressure. Volume replacement may be necessary to provide
enough preload to expand the stiffened ventricle. Tachycardia decreases the time spent in
the diastolic phase of the cardiac cycle, leading to insufficient ventricular filling time.
Conversely, bradycardia drops overall cardiac output, which may not meet the demands
of systemic circulation (Contrera et al., 2014). The atria provide nearly half of the overall
cardiac output in the setting of aortic stenosis (Paul & Des, 2017). Loss of
atrioventricular synchrony, as can occur with atrial fibrillation, will cause significant
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declines in left ventricular ejection. Systemic hypotension must not be permitted to
occur and afterload must be maintained. A decrease in the pressure gradient across the
stenotic valve will interfere with diastolic coronary artery filling and ischemia will result
(Paul & Des). The best choice of induction agent will maintain SVR while preserving
cardiac function and preventing arrhythmias or large changes in heart rate (Herrera,
2018).
Aortic Regurgitation. Failure of the aortic valve to completely close during
diastole permits blood to regurgitate into the left ventricle (Contrera et al., 2014). The
consequences are twofold. First, systemic cardiac output is decreased, as a portion of the
blood that was ejected returns to the left ventricle through the incompetent valve.
Second, increased diastolic volume, (regurgitant flow plus atrial flow) causes the
ventricle to enlarge to accommodate it (Contrera et al.). The ventricle will hypertrophy
and increase wall tension over time to generate the pressures needed to eject the increased
volume in sufficient quantity to maintain cardiac output (Paul & Des, 2017). Prolonged,
untreated aortic regurgitation can exceed the ability of the heart to compensate, resulting
in systolic heart failure (Paul & Des). The best induction agent will maintain or slightly
increased HR while lowering SVR (Herrera, 2018). Higher heart rates decrease
ventricular filling time, preventing an excessive dilation of the chamber. Decreased
afterload lowers the pressure against which the heart must pump to maintain cardiac
output, decreasing workload.
Mitral Stenosis. Mitral stenosis is the result of a failure of the mitral valve to
open completely during diastole (Contrera et al., 2014). It is not very common in the
industrialized world and is overwhelmingly associated with rheumatic heart disease.
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Pressure increases in the left atrium causing dilation and backward pressure into the
pulmonary circulation. Similar to mitral regurgitation, atrial fibrillation, pulmonary
hypertension, and right heart failure can occur. The chief insult to cardiac function with
mitral stenosis is a deficit in left ventricular filling through the narrowed valve opening
(Contrera et al.). Systemic vascular resistance should have little effect on overall cardiac
function, as mitral stenosis has little effect on left ventricular function (Herrera, 2018).
Choice of IV anesthetic should be directed at maintaining or decreasing heart rate to
prolong diastolic filling time and augment left ventricular preload (Herrera).
Mitral Regurgitation. Mitral regurgitation is a result of backward flow of blood
through an incompletely closed valve (Contrera et al., 2014). The mitral valve is
normally closed during the systolic phase of the cardiac cycle. Mitral regurgitation
permits backward flow of blood into the left atrium when the left ventricle contracts.
Backflow into the atria, coupled with forward flow from the pulmonary circulation,
causes increases in volume and pressure in the left atrium. Dilation of the left atrium
interferes with conduction of action potentials. As a result, mitral regurgitation is often
accompanied by atrial fibrillation (Contrera et al.). Continuous blood supply from the
right heart and regurgitation into the left atrium will ultimately lead to increased left heart
and ultimately left ventricular volume (Paul & Des, 2017). Left untreated, chronic mitral
regurgitation will lead to systolic heart failure; this will extend the increased backpressure
through the left atrium, into the pulmonary circulation, and into the right heart, leading to
right heart failure (Paul & Des). Choice of IV anesthetic is guided by similar factors as
with aortic regurgitation (Herrera, 2018). Decreasing SVR will lessen the pressure
against which the heart must pump to maintain cardiac output. Maintaining or slightly
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increasing heart rate will shorten the duration of ventricular filling, minimizing excessive
left ventricular pressure, and therefore decreasing the degree of retrograde flow (Herrera).
Coronary Artery Disease. Coronary artery disease (CAD) takes a significant
toll on the health of Americans. It is one of the leading causes of death in the United
States, and the incidence of CAD is increasing (Mittnacht et al., 2018). Hundreds of
thousands of people undergo coronary artery bypass grafting (CABG) procedures
annually. Coronary artery disease is the end-result of numerous physiologic processes
that contribute to the narrowing of the lumen of the arteries that provide oxygenated
blood to heart muscle cells (Contrera et al., 2014). Decreased lumen size leads to
decreased oxygen supply. Oxygen consumption is determined by combined effects of the
rate at which the heart beats, the strength of contraction, and the stress exerted against the
walls of the heart chambers by internal pressure (Hibbert, Nathan, Simard, & O’Brien,
2018). If oxygen demand exceeds supply, patients can experience symptoms including
chest pain and dyspnea (Contrera et al., 2014). Patients with long-standing ischemic
heart disease may also possess comorbid systolic heart failure and reduced ejection
fraction. These patients have even less cardiac reserve and may lack the ability to
compensate for even the slightest insult to their hemodynamics (Contrera et al.).
While there are many considerations to be made throughout the course of an
anesthetic for CABG, preventing ischemia remains the primary concern during the
induction phase. Ischemia prevention is accomplished by preservation of the patient’s
myocardial oxygen supply versus demand, ensuring that demand doesn’t exceed supply
(Mittnacht et al., 2018). Selection of an IV anesthetic for CABG should focus on
maintenance or optimization of the patient’s pre-operative hemodynamic status (Contrera
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et al., 2014). Tachycardia will increase myocardial oxygen demand. Bradycardia may
prevent the heart from producing sufficient cardiac output and coronary artery perfusion
may suffer. Sustaining the BP as close to baseline as possible is optimal. Hypertension
increases the amount of work the heart must do to overcome afterload and sustain cardiac
output. Hypotension is least desirable, resulting in decreased coronary perfusion and
oxygen supply. Increased inotropy will increase oxygen demand, while decreasing
contractility, if tolerated, will reduce it. The best IV anesthetic for CABG will be the
choice that achieves a smooth induction while preventing tachycardia and maintaining a
stable BP commensurate with the patient’s baseline (Contrera et al.).
Decision-Making in Anesthesia
Substantial incongruence exists in healthcare decisions made by different
practitioners pertaining to the same question (Cozmuta, Merkel, Wahl, & Fraenkel,
2014). Often, subject matter experts cannot agree on the proper treatment course. The
outcomes of these decisions can have significant consequences depending on the
situation and any confounding factors involved (Cozmuta et al.). Medical error is
commonplace, often with grave consequences (Stiegler & Tung, 2014). Errors frequently
lead to delays in care, especially in high pressure environments. When errors occur, they
may be accompanied by greater magnitudes of morbidity or mortality and can lead to
litigation. Real-world investigations and simulated patient scenarios have demonstrated
large variations and inconsistencies in decision-making, as well as failure to adhere to
accepted practice, and in some instances, treatment guidelines created by recognized
experts or professional associations. In the anesthesia profession, these weaknesses
affect novices and specialists alike (Stiegler & Tung).
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In a prospective, nonrandomized cohort study conducted by Munst et al., (2018),
senior physician anesthesiologists selected an IV anesthetic that the authors termed
“unjustified” based on accepted pharmacologic principles in one out of every three cases.
Medical decisions should be based upon conditions specific to the patient and the
procedure. Often, personal preference, facility custom, budgetary or other non-medical
motivations take precedence over sound science and accepted standards of practice.
Decisions made by assigning primacy to factors that are not based on sound
pharmaceutical science and in the patients’ best interest places patients at undue risk.
This is true even if no harm comes to the patient, or any possible adverse reactions can be
easily dispensed with by the anesthesia provider (Munst et al.).
Several decision-making models have been examined for the manner in which
their tenets apply to the field of anesthesia (Stiegler & Tung, 2014). A common theme in
some of the oldest decision-making models is to consider the cost versus benefit of each
medical decision and assess the potential consequences. Practitioners must be cognizant
that all of the information necessary to make that determination may not be available.
Patient and practitioner priorities may also differ (Stiegler & Tung, 2014). Providers may
gravitate toward the solution that can be accomplished in the least time with the least cost
while not incurring undue risk, while the patient may prefer the safest, most comfortable
option regardless of the cost or time involved.
Pattern-matching is commonly employed as a mechanism for decision-making
and used as a framework in medical education (Stiegler & Tung, 2014). Providers
consider the decisions they have made, or they have seen others make in similar
situations before without consequence, leading them to believe that the same decision is
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applicable in all similar circumstances. This, and other intellectual shortcuts, sacrifice
rationality for convenience and thus risk grave errors in decision-making or failure to
recognize a life-threatening situation (Stiegler & Tung). This is especially noteworthy in
situations where the provider lacks a complete information set related to the patient or
procedure (Munst et al., 2018). Critical decisions in time-sensitive situations are more
likely to be made purely on instinct, especially when the clinician feels that taking time to
consider all possible choices and outcomes is impractical (Stiegler & Tung, 2014).
A number of biases have been cited as root causes of medical errors and can
weigh considerably on the decision-making process (Stiegler & Tung, 2014). Human
nature is to seek out information that confirms one’s own conclusions rather than a
perspective challenging the legitimacy of an action. In a collaborative practice
environment, some providers may hesitate to question the decision of a senior colleague
or offer an alternative therapy, even when armed with a vital piece of information.
Experience and prestige can lead to excessive self-assuredness, blinding providers to the
possibility of other choices or failure to seek assistance when necessary. This may be
most evident when senior practitioners refuse to adopt a safer method of performing a
skill for which they have realized historical success in the face of evidence demonstrating
the superiority of the new method. Practitioners who draw their primary decision-making
influence from past experience are also vulnerable to the idea that their memory does not
mirror the details of the comparable event (Stiegler & Tung).
Additional biases that influence decision-making relate to the manner in which
the provider views the possible outcomes of the decision (Stiegler & Tung, 2014).
Emotion can play a significant role in decision-making. A provider may avoid a correct
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decision if they have experienced a negative outcome when using a particular
intervention in a similar situation. Decisions believed to produce positive results will
always be preferred to those believed to produce negative consequences (Stiegler &
Tung). There is considerable variability in how a negative experience influences a
practitioner’s future decision-making processes (Cozmuta et al., 2014). Particularly in
the practice of anesthesia, there is little in the way of patient contact after discharge and a
thorough case review is rarely undertaken absent an obvious complication or sentinel
event. Lacking any information to the contrary, decisions will be assumed to have been
correct and the desired outcome achieved (Stiegler & Tung, 2014).
The rationale behind a clinical decision is equally important as the decision itself
(Stiegler & Tung, 2014). Making the correct decision based on reasoned thinking in
context with training and experience develops competence. Choosing the correct
intervention for the incorrect reason is simply a case of good luck and can easily lead to a
different result under different circumstances. Understanding all of the factors that
influence the decision-making process improves the likelihood that providers will
recognize illogical factors influencing their behavior, guiding them to a more reasoned
and scientifically based choice. The use of cognitive aids has been shown to minimize
the likelihood that the decision-making process will be negatively prejudiced by outside
factors more likely to lead to an incorrect judgement (Stiegler & Tung). Decision trees
are one such cognitive aid.
Decision Trees in Evidence-Based Practice
Decision trees provide a logical, orderly framework that can be used by clinicians
to evaluate the factors that impact a decision and guide them to the appropriate choice
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(Lee et al., 2009). Appropriate utilization of evidence-based practice (EBP) is not merely
the regurgitation of findings from a particular study and applying them to all patients.
The individual complexities of each patient and each situation requires clinical judgement
to interpret the best evidence and relate it to the individual. Often, several decision points
are navigated on the pathway to the eventual choice (Lee et al.).
Decision trees provide a mechanism for identifying the available options and
considering the possible consequences of each step in the decision-making process
(Bamber & Evans, 2016). Even in the face of limited evidence, a properly tailored
decision tree affords the clinician a mechanism for considering what is available without
the need to perform a literature search on the spot. The evidence-based information in
the decision tree serves to augment the knowledge and experience of the clinician and is
superior to choosing a therapy on conjecture alone. The transparency provided is one of
the decision tree’s greatest assets. In some settings, the patient can be consulted to
determine their priorities, and collaborate with the provider to provide safe,
individualized care. Decision trees may be most beneficial in situations where there are
few alternatives and the incorrect choice will put the patient in jeopardy (Bamber &
Evans). Implementation of a decision tree assists practitioners to consider all of the
relevant facts, especially those that may not be routinely anticipated (Lee et al., 2009).
Next, the theoretical framework will be presented.
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Theoretical Framework
The theoretical frameworks for this project were the Information-Processing
Theory (IPT) and the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA). Initially applied to cognitive decision making in healthcare in the
late 1970’s, IPT (Figure 1) encourages clinicians to consider theories for a particular
situation, place them in context with a given set of variables, confirm or refute the theory,
and utilize the best applicable information to guide care (Joseph & Patel, 1990). Clinical
information is collected and distilled through the clinician’s body of knowledge and
experience. These factors guide the initial plan, which is refined based on any other
pertinent information the clinician seeks out. The applicability of each data point is
considered and weighed in terms of its contribution to the whole and the processed
information directs the decision. This framework assists clinicians in combining
experience, diagnostic reasoning, scientific evidence, and logic to deduce the appropriate
intervention from the options available and is commonly used in clinical decision-making
and the creation of decision trees (Banning, 2008).

Figure 1. Information Processing Theory (Information Processing Model, n.d.)
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Information Processing Theory correlates to the concept of decision-making in
anesthesia, as it parallels the traditional methods of information gathering and treatment
selection in common use. A complete medical history is obtained for all patients
receiving anesthesia as a standard of care (American Association of Nurse Anesthetists
[AANA], 2019). Anesthetists begin to formulate their treatment plan based upon the
information obtained. The anesthetist then conducts an in-person interview and physical
assessment of the patient to gather additional pertinent information. The body of clinical
data is reviewed in the context of the planned surgical procedure, and with the exception
of any unforeseen circumstance that requires modification, the plan of care is finalized
(AANA).
The current pace of turnover in the operating theater is one of many factors that
contributes to lapses in patient safety, medication errors and other adverse events
(Eichhorn, 2013). In situations of increased pressure, people take short cuts. Medication
selection may be determined based on comfort of the anesthesia provider rather than what
is best for the patient. The induction phase is a crucial time in anesthesia care during
which errors in judgement can prove fatal to a patient. Utilizing the tenets of IPT, the
preliminary steps can be undertaken to create an evidence-based decision tree to guide in
the selection of an appropriate intravenous anesthetic for patients undergoing cardiac
surgery.
Additionally, the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) was used. Adapted from the Quality of Reporting of Meta-analyses
(QUORUM) statement, PRISMA provides a comprehensive process through which an
author can identify, track, evaluate and report relevant research obtained through
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randomized controlled trials (RCTs) (Moher, Liberati, Tetzlaff, Martin, & The PRISMA
Group, 2009).
Preferred Reporting Items for Systematic Reviews and Meta-Analyses utilizes a
flow diagram (Figure 2) to assist the author in reporting the process used to select the
studies used to complete a systematic review (Moher et al., 2009). The flow diagram is
useful in demonstrating the breadth of the literature search conducted as well as
accounting for the dispensation of any studies excluded from the review. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses also utilizes a 27-question
checklist (Figure 3) for reporting on each research study included in a systematic review
(Moher et al.). The deployment of this checklist ensures that a consistent and transparent
process is used, so that reporting for each study is similar. Transparency in the research
process, combined with consistency in evaluation and reporting of included studies,
lowers the likelihood of publication bias (Moher et al.).
Next, the methods used to conduct this project will be described.
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Figure 2. PRISMA flow diagram
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Figure 3. PRISMA checklist
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Method
Purpose
The purpose of this paper was to propose a preliminary, evidence-based decision
tree to guide in the selection of an appropriate intravenous anesthetic for patients
undergoing cardiac surgery.
Design
This was an evidence-based project designed to create a decision tree. Evidence
was gathered, evaluated, analyzed, and reported in a manner similar to that which is used
to perform a systematic review.
Inclusion/Exclusion Criteria
Inclusion criteria for this systematic review included RCTs only. All patients
included in the trial were required to be adults (greater than 18 years of age), be
undergoing cardiac surgery with no other included procedure, and have anesthesia
induced via the intravenous route utilizing a single intravenous anesthetic. All patients
must have received either propofol, etomidate, or ketamine for induction. All of the
RCTs must have been published within the last ten years, written in English, and
published in a peer-reviewed journal.
Exclusion criteria included any article published greater than 10 years ago or
written in a language other than English. Additional exclusion criteria included any
patients under age 18, patients receiving an inhalation induction, studies that don’t
compare propofol, etomidate or ketamine to one of the other of these three medications,
and any patient receiving any combination of intravenous anesthetics.
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Search Strategy
A comprehensive literature search was conducted utilizing the databases
CINAHL, Academic Search Premier, Medline and PubMed. Search terms included
“induction of anesthesia”, “propofol”, “etomidate”, “ketamine”, “cardiac surgery”, and
“coronary artery bypass grafting”. After removing duplicates, articles were screened for
eligibility. Articles meeting eligibility criteria were included in the data collection
process. The search process and results were summarized in a PRISMA Flow Diagram
(Appendix A).
Data Collection
Studies selected for this systematic review were evaluated utilizing the PRISMA
Checklist as a guide. Data collected from each study was summarized in a table created
by the author (Table 1) and included in Appendix B.
Table 1
Data Collection Table
Purpose

Project
Design

Site, Sample

Method

Results

Limitations

Outcome measures for each study were extracted and summarized in a table
created by the author (Table 2), illustrated on the next page, and included in Appendix C.
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Table 2
Outcome Measures Table
Propofol

Etomidate

Ketamine

Heart Rate
Systolic Blood Pressure
Diastolic Blood Pressure
Mean Arterial Pressure
Cardiac Output
Cardiac Index
SVR
Endocrine Response

Critical Appraisal
Critical appraisal of each study was carried out using the Critical Appraisal Skills
Programme (CASP). Critical Appraisal Skills Programme was developed to assist
researchers by providing an organized method for evaluating evidence to determine
quality (Singh, 2013). When using evidence to change practice, the recommendations are
only as strong as the evidence used. Critical appraisal of research gauges the reliability
of the methodology and findings of a study. Studies conducted using the incorrect
methods for the study design, improper statistical analysis techniques, and suspect
reporting practices are not acceptable for the basis of guiding clinical practice. Each
study was critically appraised utilizing the CASP checklist shown in Table 3 and
included in Appendix D.
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Table 3
CASP Checklist for Randomized Controlled Trials
A) Are the results of the trial valid?
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were groups treated
equally?
B) What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C) Will the results help locally?
9. Can the results be applied in your
context? (or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms?

YES

CAN’T TELL

NO

YES

CAN’T TELL

NO

Cross-Study Analysis
Results were analyzed across studies utilizing Table 2 to determine overall
outcomes, themes and significance of findings. The findings of the cross-study analysis
were utilized to guide the preliminary creation of an evidence-based decision tree to
guide in the selection of an appropriate intravenous anesthetic for patients undergoing
cardiac surgery. The process used will be described in the results section.
Next, the results will be presented.
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Results
Based upon the inclusion and exclusion criteria explained above, nine articles
were identified and included in this review. The process used to identify, screen, and
select the included articles is represented graphically in Appendix A. All of the included
articles are RCTs comparing one of the chosen IV anesthetics to another of the chosen IV
anesthetics during the induction phase of general anesthesia. Study-specific data were
extracted from each article and are included in Appendix B. Outcome measures and
results were extracted from each article and are included in Appendix C. Each article
was evaluated for quality using the CASP Checklist for Randomized Controlled Trials,
which are included in Appendix D. Finally, a cross-study analysis was performed to
compare and contrast the findings of each article and is included in Appendix E.
Individual Study Analysis
The study performed by Basagan-Mogol et al. (2010) (Appendix B-1) was a
randomized controlled trial to evaluate the hemodynamic and analgesic effects of
ketamine by comparing it with propofol. All patients were undergoing CABG
procedures. Thirty patients were randomly assigned to two groups. Patients assigned to
group K received 2 mg/kg of ketamine as their IV induction agent. Patients assigned to
group P received 0.5 mg/kg of propofol as their IV induction agent. All patients
received standardized weight-based doses of morphine, midazolam, fentanyl, and
rocuronium during the induction process. Laryngoscopy was performed and intubation
was achieved using the same process in all patients. All patients were monitored using
the same invasive and non-invasive modalities. Anesthesia was maintained utilizing 0.52% sevoflurane. Adjustments to sevoflurane doses were made based upon the same
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hemodynamic parameters in all patients. Data were recorded at the same time intervals
in all patients.
Data were analyzed using the SPSS software platform to determine the mean and
standard deviation for each outcome measure. The Wilcoxon signed rank test was used
to evaluate deviations from baseline for each outcome measure. The Mann-Whitney Utest and the Kruskal Wallis test were used to compare values between the study groups.
The authors defined p < 0.05 as significant. The authors found significant decreases in
MAP and SVR one minute after induction in group P (Appendix C-1). The authors
reported that there were no adverse hemodynamic events or ST-segment abnormalities
during the study, nor was any evidence found that ketamine clearly contributed to the
level of analgesia.
Critical appraisal of this study can be found in Appendix D-1. The study
addressed a clearly focused issue. The assignment of patients to each group was
randomized and all patients were properly accounted for at the conclusion of the trial.
There was no indication as to the method used to randomize the participants, nor was
there any indication that the patient or anesthesia providers were blinded to the study
medication. The article does report that the observer responsible for recording
measurements was blinded to the study medication. The groups were similar, and with
the exception of the experimental intervention, the groups were treated equally. The
treatment effect was not discussed. The results can be applied to the local population.
All clinically important outcomes were considered. No harmful effects were reported
from the study intervention. Based upon their findings, the authors concluded that
ketamine provided more hemodynamic stability, and was therefore superior to propofol.
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The study by Pandey et al. (2012) (Appendix B-2) was a randomized controlled
trial in which the effects of propofol on hemodynamic parameters and serum cortisol
levels were compared with etomidate in patients with normal left ventricular function.
All patients were undergoing elective CABG procedures on cardiopulmonary bypass
(CPB). One hundred patients were randomly assigned to two groups. Patients assigned
to group E received 0.2 mg/kg of etomidate as the IV induction agent. Patients assigned
to group P received 2.0 mg/kg or propofol as the IV induction agent. All patients
received similar weight-based doses of morphine, phenergan, midazolam, fentanyl, and
rocuronium, which were administered within the same time frame prior to and during the
induction process. All patients were monitored using the same invasive and non-invasive
modalities. Once induced, anesthesia was maintained using sevoflurane. Data points
were recorded for the same hemodynamic parameters and cortisol levels at the same time
intervals respectively for all patients.
Statistical analysis was performed using the STATA 9.0 software platform and
data were summarized using a percentage or a range as the particular parameter required.
Baseline categorical variables were compared using the Fisher’s exact test. Baseline
continuous variables were compared using the Student’s t test. Between-group
hemodynamic variables were compared using the Student’s t test for independent
variables. The Wilcoxon Rank Sum test was used to analyze between-group data
concerning serum cortisol. The authors identified a value of p < 0.05 as a significant
finding. Outcome measures can be found in Appendix C-2. The authors reported a
significant decrease in SBP, DBP, SVR and SVRI five minutes after induction in group
P. The authors also reported a significant decrease in cortisol levels in group E and a

37

significant increase in cortisol levels in group P during weaning from CPB. The authors
further determined that etomidate provided more stable hemodynamics than propofol (p <
0.05).
Critical appraisal of this study can be found in Appendix D-2. The study
addressed a clearly focused issue. The assignment of patients to treatments was
randomized by a computer and performed as a component of the registration process
prior to the procedure in an outpatient department. All patients who entered the trial were
accounted for. While the assignment to treatment was randomized, the article does not
report on who, if anyone, was blinded. The groups were similar at the start of the trial
and were treated equally, with the exception of the experimental intervention. The
treatment effect was not discussed. The results of the study can be applied to the local
population. All clinically important outcomes were considered. No harmful effects were
attributed to the study intervention. Based upon their findings, the authors concluded that
etomidate provided more stable hemodynamics during induction when compared with
propofol and that etomidate can be used safely for induction of anesthesia for CABG on
CPB in patients with good left ventricular function. The authors further concluded that
serious decreases in serum cortisol levels produced by etomidate do not last more than 24
hours.
The study performed by Kaushal, Vatal, and Pathak (2015) (Appendix B-3) was a
prospective, randomized study to compare induction with etomidate and propofol in
cardiac surgeries. All patients were undergoing CABG, mitral valve replacement
(MVR), or aortic valve replacement (AVR) on CPB. Sixty patients were randomly
assigned to two groups. Patients assigned to group I received 2 mg/kg of propofol as the
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IV induction agent. Patients in group II received 0.2 mg/kg of etomidate as the IV
induction agent. All patients received similar doses of glycopyrrolate, midazolam,
ranitidine, ondansetron, and fentanyl within the same time frame prior to and during the
induction process. All patients were monitored using the same invasive and non-invasive
monitoring modalities. Data points were recorded for the same hemodynamic parameters
and cortisol levels at the same time intervals respectively for all patients.
The statistical analysis program utilized by the authors was not reported. Data
were compiled and summarized by reporting the percentage or range as appropriate for
the particular data point. Baseline categorical between-group variables were compared
using Fisher’s exact test. Baseline between-group continuous variables were compared
using Student’s t-test. Between-group hemodynamic variables were compared using
Student’s t-test for independent variables. Between-group comparison of cortisol data
was performed using the Wilcoxon Rank Sum test. The authors identified a value of p <
0.05 as a significant finding. Outcome measures can be found in Appendix C-3. The
authors reported a significant decrease in SBP, DBP, MAP, CO, and CI after induction,
after intubation, and five minutes post-intubation in group I. After intubation, SVR
continued to decrease in group I while it increased above baseline in group II. The
authors further reported that serum cortisol decreased significantly in group II while
increasing significantly in group I. Serum cortisol in both groups returned to baseline
levels 24 hours post-operatively (p < 0.001).
Critical appraisal of this study can be found in Appendix D-3. The trial addressed
a clearly focused issue. The assignment of patients to treatment was randomized. All
patients who entered the trial were accounted for. The authors reported that
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randomization was performed by opening a sealed envelope containing the group
assignment immediately prior to entering the operating room. The degree to which
patients, health workers, and study personnel were blind to treatment was not specifically
addressed. The methods used to assign particular patients to a particular group were not
discussed. Upon opening the envelope, the anesthesia provider would be aware which
medication would be administered to the patient; however they would have not had any
forewarning. The groups were similar at the start of the trial and were treated equally
with the exception of the experimental intervention. The treatment effect was not
discussed. The results can be applied to the local population. All clinically important
outcomes were considered. No harmful or adverse outcomes were reported. The authors
concluded that etomidate provided a more stable hemodynamic profile during the
induction of anesthesia for patients with poor LV function when compared with propofol
and that any observed fluctuation in cortisol levels did not result in untoward effects.
Based upon their findings the authors determined that etomidate can be used safely for
induction of anesthesia for CABG, MVR, or AVR procedures on CPB in patients with
poor left ventricular function.
A study performed by Shivanna et al. (2015) (Appendix B-4) was a prospective,
double blind, randomized comparative study to evaluate the hemodynamic effects of
etomidate in comparison to that of propofol during induction of general anesthesia. All
patients were undergoing CABG on CPB. Forty patients were randomly assigned to two
groups. Induction was carried out using an infusion of the assigned medication rather
than a single bolus dose. Patients in group P received 0.5 mg/kg/min of propofol as the
IV induction agent. Patients in group E received 0.05 mg/kg/min of etomidate as the IV
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induction agent. All patients received similar doses of morphine, promethazine,
midazolam, fentanyl, and rocuronium within the same time frame prior to or during the
induction process. All patients were monitored using the same invasive and non-invasive
monitoring modalities. Anesthesia was maintained using sevoflurane in all patients.
Hemodynamic fluctuations were treated utilizing the same parameters and same
interventions for all patients. Data points were recorded for the same hemodynamic
parameters at the same time intervals in all patients.
Statistical analysis was performed using the SPSS, STATA, Med Calc, and Systat
software platforms. Patient characteristics were examined using the Chi-square test.
Between-group comparison was performed using the unpaired t-test. The authors
delineated three different levels of significance. A p-value of 0.05-0.10 was categorized
as having “suggestive significance”. A p-value of 0.01-0.05 was categorized as
“moderately significant”. A p-value <0.01was categorized as “strongly significant”. The
authors performed a power analysis of previous studies to determine that a sample size of
20 patients per group was required to achieve a power of 80% and a 0.05 for detection of
the desired hemodynamic changes. Outcome measures can be found in Appendix C-4.
The authors reported that MAP decreased in group P more than group E; however the
difference was not statistically significant. The authors reported that SVR decreased in
group P in a moderately significant manner (p=0.022). The authors further reported that
after intubation, SVR increased in both groups, with the patients in group E
demonstrating a statistically significant larger increase than group P (p=0.003).
Critical appraisal of this article can be found in Appendix D-4. The study
addressed a clearly focused issue. The assignment of patients was randomized. All
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patients who entered the study were accounted for. Participants were blinded to the
treatment. The groups were similar at the start of the trial. The groups were treated
equally, with the exception of the experimental intervention. The treatment effect was
not discussed. The results can be applied to the local population. All clinically important
outcomes were considered. No harmful or untoward events were reported. Based upon
their findings, the authors concluded that propofol produced a greater reduction in
contractility, arterial blood pressure, and afterload when compared with etomidate when
used as an induction agent in patients with coronary artery disease. The authors further
concluded that etomidate was less effective than propofol in preventing a patient’s stress
response to intubation.
A study performed by Kamath, Kamath and Patla (2016) (Appendix B-5) was a
prospective, randomized study to compare propofol with etomidate with respect to
hemodynamic stability during induction of anesthesia for open cardiac surgical
procedures. All study participants were undergoing elective cardiac surgical procedures,
which included CABG, MVR, and AVR. Sixty patients were randomly assigned to two
groups. Group A received 1.5 mg/kg of propofol as the IV induction agent. Group B
received 0.2 mg/kg of etomidate as the IV induction agent. All patients received similar
actual or weight-based doses of ranitidine, diazepam, fentanyl, midazolam, and
rocuronium prior to or during the induction process. After the induction agents and all
other adjuncts were administered, all patients were ventilated with 100% oxygen and 1%
sevoflurane for three minutes prior to intubation. All patients were monitored using
identical invasive and non-invasive monitoring modalities. Data points were collected
for the same hemodynamic parameters at the same time intervals for all patients.
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Statistical analysis was performed utilizing the SPSS software platform. Baseline
values were compared using the independent Student’s t-test. Continuous variables were
compared using the independent Student’s t-test. The authors identified a p-value of <
0.05 as a significant finding. Outcome measures can be found in Appendix C-5. The
authors reported a significant decrease in SBP, MAP, CO and CI after induction in group
A. The authors reported a significant increase in DBP, CO and CI after intubation in
group A. The authors reported a significant increase in MAP, CVP and PCWP five
minutes after intubation in group A. No significant changes were noted in group B for
any data point at any time.
Critical appraisal for this article can be found in Appendix D-5. The article
addressed a clearly focused issue. The assignment of patients was randomized using
closed envelope technique. All patients who entered the trial were properly accounted
for. It was not clear from the article whether patients, health care workers, or study
personnel were blind to treatment. Groups were similar at the start of the trial. All
participants were treated equally, with the exception of the experimental intervention.
Treatment effect was not discussed. The results can be applied to the local population.
All clinically important outcomes were considered. No harmful or untoward effects were
reported. Based upon their findings, the authors concluded that etomidate provides a
more favorable hemodynamic profile when compared with propofol when used for
induction of anesthesia in cardiac surgical procedures.
A study performed by Soleimani et al. (2017) (Appendix B-6) was a double-blind,
randomized clinical study to compare the hemodynamic responses to propofol, etomidate,
and diazepam following anesthesia induction, laryngoscopy, and intubation in patients
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with low ejection fraction. While this study investigated a medication outside the scope
of this paper (diazepam), the authors reported data specifically comparing the
hemodynamic responses to propofol and etomidate, which is directly applicable and
meets the inclusion criteria. All study participants were undergoing elective CABG with
CPB. One hundred fifty patients were randomly assigned to three equal groups. Patients
in group A received 1.5 mg/kg of propofol as the IV induction agent. Patients in group B
received 0.2 mg/kg of etomidate as the IV induction agent. Patients in group C received
0.3 mg/kg of diazepam as the IV induction agent. All patients received identical weightbased doses of midazolam, fentanyl, and succinylcholine during the induction process.
All patients were monitored utilizing the same invasive and non-invasive monitoring
modalities. Data points were collected for the same hemodynamic parameters at the
same time intervals for all patients.
Statistical analysis was performed utilizing the SPSS software platform. Normal
distribution of data determination was performed using the Kolmogorov-Smirnov test.
Quantitative variable analysis was performed using ANOVA and the Bonferroni test.
The authors identified a p-value < 0.05 as a significant finding. Outcome measures can
be found in Appendix C-6. The authors reported a significant decrease in SBP, DBP, and
MAP in groups A, B, and C one minute after induction and before laryngoscopy, with the
reductions in group C being to a lesser degree than groups A and B. These measurements
returned to near baseline in groups B and C while remaining significantly reduced in
group A one minute after laryngoscopy. The authors reported a significant decrease in
mean HR one minute after induction in groups A and B, which did not occur in group C.
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The authors reported that a significantly larger percentage of patients in group A required
rescue administration of ephedrine when compared with groups B and C.
Critical appraisal for this article can be found in Appendix D-6. The study
addressed a clearly focused issue. The assignment of patients to treatments was
randomized using the sealed envelope technique. Allocation to a particular group was
performed based upon a numbers list that was computer-generated by a nurse who was
unaware of the study groups. All patients who entered the trial were accounted for at its
conclusion. All participants, including the anesthesia provider of record, were blinded to
the treatment. To ensure patient safety, medications were prepared by a qualified
anesthesia provider who was not involved in the study. Each of the study medications
was prepared in an equal volume and syringes were covered with tape to conceal any
identifying characteristics of the medication contained within. The groups were similar
at the start of the trial and were treated equally, with the exception of the experimental
intervention. Treatment effect was not discussed. The results can be applied to the local
population. Diazepam is not traditionally used as an IV induction agent. The data
reported comparing propofol and etomidate are directly applicable to this paper. All
clinically relevant outcomes were considered. No harmful or untoward events were
reported. The authors’ conclusion was that diazepam provided more favorable
hemodynamics than propofol and etomidate. The extraction of data comparing propofol
and etomidate demonstrated that propofol results in a greater decrease in SBP, DBP, and
MAP when compared to etomidate and the decrease continues for a greater length of time
in patients receiving propofol. This is consistent with the substantially greater need for
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rescue administration of ephedrine for patients receiving propofol (28%) compared with
those receiving etomidate (4%).
A study performed by Mala and Narmada (2017) (Appendix B-7) was a
prospective, randomized study to compare the hemodynamic profile and hormonal
alteration between etomidate and propofol following induction of anesthesia. All patients
included in this study were undergoing elective CABG with CPB. Thirty patients were
randomly assigned to two equal groups. Patients in the propofol group received 2 mg/kg
of propofol as the IV induction agent. Patients in the etomidate groups received 0.2
mg/kg as the IV induction agent. All patients were monitored utilizing the same invasive
and non-invasive monitoring modalities. Data were collected for the same hemodynamic
parameters at the same time intervals for all patients.
The authors reported that statistical analysis was performed, however the methods
used were not reported. The authors identified a p-value < 0.05 as a significant finding.
Outcome measures can be found in Appendix C-7. The authors reported a significant
reduction in SBP compared to baseline in the propofol group after induction, which was
much lower five minutes after intubation. The authors reported a significant decrease in
CI from baseline in the propofol group when measured two and three minutes following
induction. The authors reported a 50% decrease in serum cortisol at the initiation of CPB
in the etomidate group, while serum cortisol in the propofol group was nearly double the
baseline level.
Critical appraisal of this article can be found in Appendix D-7. The trial
addressed a clearly focused issue. The authors reported that assignment of patients to
treatments was randomized; however, the randomization method was not provided. The
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authors reported that the patients were randomly assigned to two groups, but there was no
further discussion as to the disposition of these patients. The groups were similar at the
start of the trial. The treatment regimen outside of the experimental intervention was not
discussed. The authors neither stated that the regimen was the same across all patients,
nor stated that it was different. Treatment effect was not discussed. The results can be
applied to the local population. All clinically important outcomes were considered. No
harmful or untoward events were reported. Based upon their findings, the authors
concluded that induction with etomidate provided more hemodynamic stability when
compared with propofol. The authors reported that etomidate caused a transient
reduction in serum cortisol which normalizes within two hours. The authors conclusory
statement was that etomidate can therefore be used safely for induction of anesthesia in
patients with good left ventricular function for CABG with CPB.
A study performed by Meena et al. (2017) (Appendix B-8) was a prospective
randomized study to compare the effects of etomidate and propofol on hemodynamic and
serum cortisol levels. All patients included in the study were undergoing elective CABG
with CPB. Sixty patients were randomized into two equal groups. Patients in group A
received 0.3 mg/kg of etomidate as their IV induction agent. Patients in group B received
2.0 mg/kg of propofol as their IV induction agent. All patients received similar weightbased doses of morphine, promethazine, fentanyl and rocuronium prior to or during the
induction process at the same time intervals. All patients were monitored using the same
invasive and non-invasive monitoring modalities. Data were collected for the same
hemodynamic parameters and serum levels at the same time intervals for all patients.
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Statistical analysis was performed utilizing the SPSS software platform.
Quantitative measurements were reported with means and standard deviations. The
unpaired t-test was used to analyze the between-group difference between the means.
The paired t-test was used to analyze the within-group difference between the means.
The authors reported qualitative data, which only includes patient age, as a number and
percentage. The chi square test was used to analyze the differences in qualitative data.
The authors maintained a significance level of 95% for all analyses. Outcome measures
can be found in Appendix C-8. The authors reported a significant decrease in SBP, DBP,
SVR and SVRI in group B after induction. The authors reported a significant increase in
HR and SBP after intubation in group A. The authors reported a significant decrease in
serum cortisol when coming off bypass in group A, with a significant increase in group
B.
Critical analysis of this article can be found in Appendix D-8. The trial addressed
a clearly focused issue. The assignment of patients to treatments was randomized.
Randomization was performed using the chit-in-box method. All patients were
accounted for at the trial’s conclusion. The authors did not report on the blinding of any
participants. The groups were similar at the start of the trial. While the calculated
distribution of patients according to sex was not statistically significant, 85% of the
patients enrolled in the study were male. In group A, there were only two females, while
in group B, there were only seven females. The authors reported that there were no
statistically significant differences between groups; however, the within-group gender
distribution is noteworthy. The groups were treated equally, with the exception of the
experimental intervention. Treatment effect was not discussed. The results can be
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applied to the local population. All clinically important outcomes were considered. The
authors reported four instances of pain with injection, one instance of severe hypotension,
and two instances of bradycardia in group B, and 2 instances of myoclonus in group A.
Based upon their findings, the authors concluded that etomidate prevented the surge in
serum cortisol at the institution of CPB that is seen when propofol is used and that
etomidate produced a more stable hemodynamic profile than propofol during induction
without blunting the sympathetic stimulation to laryngoscopy.
A study performed by Hannam et al. (2019) (Appendix B-9) was a randomized
controlled superiority trial to test the hypothesis that etomidate is superior to propofol for
induction of anesthesia in relation to hemodynamic stability over the first 10 minutes
after induction in patients undergoing cardiac surgery. All patients enrolled in the study
were undergoing elective CABG, valve surgery, CABG/valve surgery, and thoracic aorta
surgery. One hundred fifty patients were enrolled in the study, which was conducted in
two phases. Initially, 156 patients were randomized. After randomization, six patients
were not included in the final results. The authors reported that four patients were
excluded just prior to surgery, while two were not included due to corrupted electronic
medical records. Each phase included two patient groups, each of which were
randomized to receive either propofol or etomidate as the IV induction agent.
Randomization was completed prior to the start of phase I, resulting in sample size
variation between and within phases. The first phase was open-label, during which the
anesthesia provider was not blinded to the treatment drug (n=76; propofol = 40,
etomidate =3 6). The second phase was closed-label, during which all clinical staff were
blinded (n=74; propofol = 35, etomidate = 39). All patients received midazolam,
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fentanyl, and a non-specific non-depolarizing neuromuscular blocking medication prior
to or during the induction process. The doses for these medications, and choice of nondepolarizing neuromuscular blocking medication, were not standardized and left to the
discretion of the anesthesia provider. Anesthesia was induced using non-standardized
doses of the IV induction agent. Anesthesia providers were permitted to titrate the
administration at their discretion to achieve loss of consciousness. All patients were
monitored utilizing the same invasive and non-invasive monitoring modalities. Data
were collected for the same hemodynamic parameters at the same time intervals for all
patients.
The authors reported that their primary endpoint for the purpose of statistical
analysis was determining the total use of vasopressor medications within the first 10
minutes after induction of anesthesia. This data was reported as either requiring
vasopressor medication or not requiring vasopressor medication and between group
comparisons were made using logistical regression, summarized as odds ratios with 95%
confidence intervals. The authors reported that stratification was performed to control for
variations in anesthetist behavior, open versus closed-label phases, and baseline MAP.
Outcome measures can be found in Appendix C-9. Based upon their findings, the authors
concluded that propofol produced a 34% greater reduction in MAP when compared with
etomidate and that etomidate provided a superior hemodynamic profile to propofol.
Critical appraisal can be found in Appendix D-9. The trial focused on a clearly
focused issue. The assignment of patients was randomized. All patients who were
entered into the trial were accounted for at the end of the study. The study was
performed in two phases. Phase I was conducted in an open-label format. Phase II was
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conducted in a closed-label format during which all clinical and study staff were blinded
to the induction drug. Between group makeup was similar between groups. Withingroup makeup was skewed substantially toward male patients. The groups were treated
equally insofar as they received the same medication regimen, with the exception of the
treatment intervention. Dosing of the IV induction agent, as well as the other adjunct
medications, varied at the discretion of the individual anesthetist. The formulation of
etomidate was changed for phase II. To further blind the anesthesia provider to the
treatment medication, a lipid-based emulsion formulation of etomidate was utilized,
rendering it visually indistinguishable from propofol. The treatment effect was not
discussed. The results can be applied to the local population. All clinically important
outcomes were considered. There were no harmful or untoward events reported. The
authors did comment on the safety of their approach. They reported that when both
induction agents were visually indistinguishable, with a color and consistency
traditionally associated with propofol, anesthetists treated both medications as though
they were propofol. Since the lipid-based etomidate emulsion was not diluted so that the
per milliliter concentration for the appropriate weight-based dose range was similar to
propofol, this led to a more than three-fold increase in actual dose of etomidate
administered during the blinded phase. The authors admitted that this method of blinding
caused a deviation from practice in the blinded phase that could have put patients at risk
and negatively affected outcomes; however no adverse effects were reported.
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Cross-Study Analysis
The cross-study analysis can be found in Appendix E. A single study was found
(Basagan et al., 2010) comparing propofol to ketamine. All of the remaining studies
(Hannam et al., 2019; Kamath et al., 2016; Kaushal et al., 2015; Mala & Narmada, 2017;
Meena et al., 2017; Pandey et al., 2012; Shivanna et al., 2015; Soleimani et al., 2017)
compared propofol to etomidate and all investigated and compared the hemodynamic
changes associated with the administration of each medication. Three of the studies
(Kaushal et al., 2015; Meena et al., 2017; Pandey et al., 2012) investigated cortisol
response to propofol and etomidate in addition to the hemodynamic changes.
Dosing of each medication was generally consistent across studies. Bolus doses
of propofol were used at 2.0 mg/kg (Kaushal et al., 2015; Meena et al., 2017; Pandey et
al., 2012; Soleimani et al., 2017) and 1.5 mg/kg (Kamath et al., 2016; Mala & Narmada,
2017). An infusion of 0.5 mg/kg/min of propofol was used in study 4 (Shivanna et al.,
2015). Propofol was dosed at the anesthesia provider’s discretion in study 9 (Hannam et
al., 2019). Bolus doses of etomidate were used at 0.2 mg/kg (Kamath et al., 2016;
Kaushal et al., 2015; Mala & Narmada, 2017; Meena et al., 2017; Pandey et al., 2012)
and 0.3 mg/kg (Soleimani et al., 2017). An infusion of 0.05 mg/kg/min of etomidate was
used in study 4 (Shivanna et al., 2015). Etomidate was dosed at the anesthesia provider’s
discretion in study 9 (Hannam et al., 2019). A bolus dose of ketamine was used at 0.2
mg/kg in study 1 (Basagan et al., 2010).
The administration of propofol was generally associated with a clinically
significant reduction in hemodynamic parameters after induction. The administration of
propofol was associated with a reduction in SBP in all studies. Diastolic blood pressure
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was reduced in studies two, three, six and eight (Kaushal et al., 2015; Mala & Narmada,
2017; Pandey et al., 2012; Soleimani et al., 2017). Mean arterial pressure was reduced in
studies one, three, four, five, six and nine (Basagan et al., 2010; Hannam et al., 2019;
Kamath et al., 2016; Kaushal et al., 2015; Mala & Narmada, 2017; Shivanna et al., 2015).
Systemic vascular resistance was reduced in studies one, two, three, and eight (Basagan
et al, 2010; Kaushal et al., 2015; Pandey et al., 2012; Soleimani et al., 2017). Study six
(Mala & Narmada, 2017) reported that a greater number of patients receiving propofol
required rescue administration of ephedrine when compared with etomidate. The
administration of etomidate was associated with an increase in DBP, CO and CI (Mala &
Narmada, 2017), as well as HR and SBP (Soleimani et al., 2017) after intubation.
Etomidate was associated with a decreased cortisol level (Kaushal et al., 2015; Meena et
al., 2017; Pandey et al., 2012), while propofol was associated with an increased cortisol
level (Kaushal et al., 2015; Meena et al., 2017; Pandey et al., 2012). No statistically
significant changes in hemodynamic parameters were associated with the administration
of ketamine. Alterations in cortisol in response to ketamine were not studied.
Creation of Decision Tree
Based upon the information collected during the cross-study analysis, a decision
tree (Figure 4, p. 55) was constructed to guide the anesthesia practitioner to the most
appropriate choice of IV anesthetic for a particular patient. First, any known allergy,
hypersensitivity, comorbid condition, or known genetic condition that precludes the use
of a particular medication should be considered. Next, the determination must be made
as to whether the patient is in a moribund state or experiencing an emergency situation.
In these situations, it may be necessary for the anesthesia provider to make risk versus
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benefit judgments based upon their experience and to choose the medication that he/she
believes provides the greatest likelihood of causing the least harm. Finally, decision
points would be based upon the known pathophysiology of various structural heart
conditions and the IV anesthetic whose hemodynamic effects profile provides the
conditions best suited for the particular patient.
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IV Induction Agent for Cardiac Surgery Decision Tree
Pertinent Medication
Disqualified

Allergy, Hypersensitivity or
Contraindicating Condition

YES

KEY

•
•

NO

Ketamine

Moribund Patient or
Emergency Situation

YES

•

•

NO

Ketamine
Contraindicated

Propofol,
Etomidate or
Ketamine

Figure 4. Decision tree

Coronary Artery Disease

YES

NO

NO

NO

Aortic or Mitral
Stenosis

Aortic or Mitral
Regurgitation

YES

YES

Etomidate or
Ketamine

Propofol

Blue Box – Decision Points
Red Box – STOP
• Consider contraindications and
disqualifications
Orange Box – Recommendation based
on research outside this project
Green Box – Best Choice
• No evidence to support choosing
etomidate or ketamine over the
other
• Use best clinical judgment

NO

Propofol,
Etomidate or
Ketamine
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Utilization of the Decision Tree
After a thorough review of the patient’s medical record and pre-admission testing,
the anesthesia provider performing the induction should perform a detailed pre-anesthesia
assessment and physical exam. Based upon those findings, the anesthesia provider
should refer to the decision tree to select the IV induction agent best suited for the
patient’s condition. It’s understood that an emergency situation may preclude a thorough
medical record review and/or pre-anesthesia assessment. In this instance, every attempt
should be made to identify the patient’s known medication allergies and pertinent
medical history by any means possible. The decision tree is not a substitute for clinical
judgment. The anesthesia provider should not administer any medication to a patient
they feel would be harmful, regardless of the recommendation obtained from the decision
tree. Personal preference, facility custom, budgetary, or other non-medical motivations
are not a substitute for evidence-based practice, and should not be used as an excuse to
ignore the decision tree.
The decision tree should be read from top to bottom. A key is provided for
reference. Items in blue boxes are considered decision points. Items in red boxes should
prompt the anesthesia provider to stop and consider eliminating the applicable medication
as an option for the patient. Items in orange boxes are based upon recommendations
from research outside the scope of this project. Items in green boxes are the best choice
based upon the research performed during this project.
First, any medication for which a patient has a known allergy or hypersensitivity
should not be used. This includes medical or genetic conditions for which administration
of the particular medication could cause harmful side effects. Next, the anesthesia
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provider should consider whether or not the patient is suffering from an emergency
situation rendering them hemodynamically unstable. Ketamine has been recognized as
the best choice in hemodynamically unstable emergency situations by international
organizations (Morris et al., 2009). Next, the anesthesia provider should consider
whether or not the patient suffers from coronary artery disease. A “yes” answer
eliminates ketamine as a medication choice and the anesthesia provider should continue
down the decision tree without considering ketamine. A “no” answer permits the
anesthesia provider to continue down the decision tree maintaining ketamine in their
repertoire. Next, the anesthesia provider should consider heart valve findings from the
pre-operative echocardiogram. The presence of stenotic or regurgitant valve lesions will
guide the direction of travel down the decision tree where it splits into two columns. The
choice of IV induction agent most appropriate for the patient is based upon the
recommendation in the green box. Where multiple options are listed, clinical judgment
should guide the selection. There is no evidence to support the selection of ketamine or
etomidate over the other.
Next, the summary and conclusions will be discussed.
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Summary and Conclusions
Anesthesia providers have multiple IV anesthetic medications at their disposal
from which to choose when selecting the agent best suited for their patients’
comorbidities and the proposed surgical procedure (Nagelhout, 2014). Patients
presenting for cardiac surgery are likely to bring a plethora of comorbidities affecting end
organ function. These patients are high risk, as are the surgeries. It’s imperative that the
anesthesia provider facilitate a smooth and stable induction to protect the patient from
additional physiologic compromise.
The purpose of this paper was to propose a preliminary, evidence-based decision
tree to guide in the selection of an appropriate intravenous anesthetic for patients
undergoing cardiac surgery. Two theoretical frameworks were utilized to guide this
project. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) was used to guide the research process. Information Processing Theory (ITP)
was implemented to guide development of the decision tree. A comprehensive literature
search yielded nine RCTs meeting inclusion criteria (Appendix A). Data and outcome
measures were collected from each RCT and summarized in Appendices B and C. The
Critical Appraisal Skills Programme (CASP) was applied to each RCT, with results
summarized in Appendix D. The cross-study analysis is detailed in appendix E. The
literature review and cross-study analysis guided the creation of the decision tree. The
decision tree can be found in Figure 4.
The decision tree first accounts for allergies and hypersensitivities, followed by
conditions for which the administration of a particular IV anesthetic could cause severe
or life-threatening consequences notwithstanding the hemodynamic changes. For
example, etomidate is contraindicated in patients with porphyrrias (Nagelhout, 2014).
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Emergency situations must be handled differently than elective cases. Ketamine is
generally recognized as a vital medication during emergency situations (Morris et al.,
2009). The cross-study analysis guided the development of the subsequent steps in the
decision tree.
Principal findings of the cross-study analysis include the association of a
clinically significant reduction in several hemodynamic parameters with propofol when
compared with ketamine and etomidate. Ketamine was associated with superior
maintenance of MAP and SVR. Across applicable studies, etomidate was associated with
a more stable hemodynamic profile than propofol. When comparing data collection
points across studies comparing propofol to etomidate, results were relatively consistent,
depending on hemodynamic parameters measured, within-procedure collection intervals,
and conclusions reported. Generally, patients receiving propofol experienced a clinically
significant decline in blood pressure (SBP, DBP and/or MAP) after induction when
compared with etomidate. Two studies (Kamath et al., 2016; Meena et al., 2017)
reported an increased HR and some blood pressure parameter after intubation in patients
receiving etomidate. This is consistent with etomidate’s lack of sympathetic blunting and
customary patient response to intubation. Kamath et al (2016) also reported increased
CO and CI after intubation when etomidate was used, which is consistent with the
physiologic changes seen with a sympathetic discharge during intubation. Two studies
(Kaushal et al., 2015; Soleimani et al., 2017) reported a significant decrease in SVR with
etomidate, although to a lesser degree than propofol. In studies utilizing cortisol response
as an outcome measure, etomidate was generally associated with a decrease in cortisol
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levels while propofol was associated with an increase. Long-term effects of cortisol
response were outside the scope of these studies.
Propofol, etomidate, and ketamine each have their place in the care of cardiac
surgery patients. Anesthesia providers can utilize their understanding of the
pharmacology of IV anesthetics and the pathophysiology of various structural heart
diseases to guide their decision-making. In patients with conditions having
hemodynamic needs at odds with each other (i.e. CAD and aortic stenosis), it may be
necessary to choose “the lesser of two evils” and select the medication that will generate
the more easily addressed side effects. In general, patients presenting with conditions for
which blood pressure and SVR must be maintained, such as patients with stenotic valve
pathologies, would benefit from a medication that preserves each, such as etomidate or
ketamine. Ketamine should be avoided in patients for which an increased HR and
myocardial oxygen demand would be detrimental. Myocardial ischemia during induction
could ultimately lead to additional myocardial damage. Etomidate, or carefully titrated
propofol, would provide the safest induction in these patients. Propofol’s best use will be
in patients for which a decrease in SVR is desirable, such as in regurgitant valve
pathologies. Ketamine’s best use may be in the case of emergency procedures or in
patients where preservation of compensatory mechanisms is paramount. Its
bronchodilatory effects may also benefit patients with coexisting severe reactive airway
disease.
Limitations were identified at various points throughout the completion of this
project. One lone study meeting the inclusion criteria was found comparing propofol
with ketamine. The findings in this study are consistent with what would be expected
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based on the pharmacology of each medication and the known physiologic responses. No
studies were located comparing etomidate with ketamine during cardiac surgery. This
likely dictates that any decision regarding medication selection between the two be
dependent upon the known indications and contraindications to each medication rather
than direct evidence demonstrating the benefit of one over the other. Dosing of
medications was not consistent across all studies. Differing bolus doses were seen across
studies and one study employed infusions rather than boluses. Another study permitted
the anesthesia provider to administer the assigned medication by the method and dose of
their choosing. This interferes with the ability to demonstrate the safest
dose/administration procedure yet does establish that the patients’ responses are
reasonably consistent across protocols.
The process used to develop this project also presented limitations. The nature of
modern evidence-based practice favors the utilization of the most current information.
Limiting the inclusion criteria to studies performed in the previous ten-year period
increased the likelihood that data further supporting or disputing the conclusions were
omitted. Excluding research published in languages other than English may have had the
same effect. The researcher’s lack of experience conducting projects of this nature may
also have limited the quality of the research and the veracity of its findings or
recommendations.
Next, the recommendations and implications for advanced nursing practice will
be discussed.
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Recommendations and Implications for Advanced Nursing Practice
Advanced Practice Registered Nurses (APRN) are perfectly positioned as leaders
in the healthcare system. In addition to their extensive education and experience at the
bedside in the RN role, APRNs are trained to provide comprehensive and compassionate
care within their area of expertise. Evidence-based practice is the foundation of nursing
education at all levels. Nurses are trained to seek out the best available evidence,
evaluate that evidence, and implement their findings into clinical practice so as to provide
their patients the best possible care. The cumulative benefits of APRN experience,
education and capability uniquely qualify them to meet the complex needs of their
patients.
Certified Registered Nurse Anesthetists in particular are in a position to lead
innovation practice improvements. The rigor of CRNA education, coupled with its
strong foundation in the sciences, augments the evidence-based, patient-centered nursing
care all CRNAs learned to provide at the bedside. Certified Registered Nurse
Anesthetists are often the sole anesthesia provider, especially in rural areas where
resources are limited. As experts in the provision of all modalities of anesthesia care in
all settings, CRNAs are sought after for their expertise and leadership skills. They are in
a unique position to assume a leadership role and champion practice improvements
through the implementation of evidence-based interventions.
The utilization of two theoretical frameworks played a pivotal role in realizing the
benefits of this project. Most research studies focus on answering a particular question or
set of questions. These studies may or may not discuss the manner in which practitioners
could implement those answers into generalized practice. The combination of the two
frameworks used (PRISMA and IPT) not only assisted in finding and processing the
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available evidence on the research topic, but also served as the foundation for the
subsequent steps necessary to translate the evidence into practice. In order for new
evidence to extend beyond the esoteric and abstract, we must be able to demonstrate the
mechanism by which it can be used for the betterment of patients. Understanding the
decision-making process, especially by healthcare practitioners, is vital to establishing the
basis for moving research findings from the classroom to the bedside. It would be
beneficial for nursing educators and change leaders in the healthcare industry to expand
their research processes to include decision-making theories as a compulsory component.
This type of research supports culturally competent care to diverse populations
and works toward ensuring ethical practice by all caregivers. Each and every patient
deserves the highest level of care, backed by the latest evidence, to guide their treatment
and see them through to the best possible outcome. Sound decision-making practices
based on solid evidence, distilled through an interdisciplinary team of expert clinicians
can achieve those goals. This project lends some insight into how APRNs in general, and
CRNAs in particular, can use research to enhance patient care. They are uniquely
prepared to lead these efforts.
Certified registered nurse anesthetists (CRNAs) in particular are positioned to
lead a team of caregivers from multiple disciplines to see the patient through the surgical
experience. Certified Registered Nurse Anesthetists are educated to practice
independently while providing all types of anesthesia to all patient populations. Decision
trees such as the one developed in this project, as well as other decision-making aids, will
complement the education, experience, and critical-thinking expertise of CRNAs as they
work to provide the best possible care to their patients. Nurse anesthesia educational
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programs are the ideal setting to nurture the thought processes and leadership skills
needed to increase the ubiquity of evidence-based guidelines and decision trees.
Beginning in 2025, all graduates of nurse anesthesia educational programs will be
required to earn a Doctor of Nursing Practice (DNP) for entry into practice (Madsen
Gombkoto et al., 2014). Many programs have already transitioned to a DNP curriculum.
With the DNP program requirement of the completion of a practice improvement project,
all new CRNAs will launch their career with experience in designing and implementing
evidence-based practice improvements. The integration of decision-making processes
should be a compulsory component of these projects.
Much work remains to be done to overcome dated attitudes and individual
comfort zones. The first step would be to recognize the subject areas with the greatest
discrepancy between current behavior and best practices. Further research is needed to
identify topic areas with the greatest inconsistencies to guide the prioritization of practice
improvement efforts. Another area of future research could involve revisiting past
evidence-based implementation attempts which failed to produce the desired results.
Incorporating research related to decision-making in healthcare could bridge the gap
between the practice improvement and its successful implementation with optimal
results.
Decision trees such as the one developed during this project can improve practice
to coincide with the most current research on a particular topic and support consistency
within an organization. This effort requires collaboration among all stakeholders and
across multiple disciplines. Some changes may necessitate organizational policy
modifications, or perhaps legislative action. Focused, professional leadership is
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necessary to navigate the process. Certified Registered Nurse Anesthetists are the ideal
expert providers to utilize their education, experience and position as respected APRNs to
champion these efforts.
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Appendix A

Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n = 38 )

Additional records identified
through other sources
(n = 0 )

Eligibility

Screening

Records after duplicates removed
(n = 38 )

Records screened
(n = 24)

Records excluded
(n = 8 )

Full-text articles assessed
for eligibility
(n = 16 )

Full-text articles excluded,
with reasons
(n = 7)

Included

Studies included in
qualitative synthesis
(n = 9)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 9 )

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097
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Appendix B
Table B-1
Basagan-Mogol, E., Goren, S., Korfali, G., Turker, G., & Kaya, F. N. (2010). Induction of anesthesia in coronary artery bypass graft
surgery: The hemodynamic and analgesic effects of ketamine. Clinics, 65(2), 133-138. https://doi.org/10.1590/S1807
59322010000200003
Research Question

Project Design

Site, Sample

To evaluate the
hemodynamic and
analgesic effects of
ketamine by comparing
it with propofol starting
at the induction of
anesthesia until the end
of sternotomy in
patients undergoing
coronary artery bypass
grafting surgery

Randomized controlled
trial with two groups,
each comprised of 15
patients, undergoing
CABG

Thirty patients, ages
35-75, ASA class III or
IV, scheduled for
elective CABG

Group K (n=15):
Received ketamine as
IV induction agent
Group P (n=15):
Received propofol as
IV induction agent

All patients had good
left ventricular function
(defined as LVEF >
40% and LVEDP < 15
mmHg).
Excluded patients:
valve disease, diabetes,
severe renal or hepatic
dysfunction, drug or
alcohol abuse and those
presenting for a second
or subsequent CABG
procedure

Method
All patients received
similar weight-based
doses of morphine,
midazolam, fentanyl,
and rocuronium.
Group K patients
received 2 mg/kg
ketamine.
Group P patients
received 0.5 mg/kg
propofol.
Hemodynamic
measurements: preinduction, one minute
after induction, one,
three and ten minutes
after intubation, one
minute after incision,
and one minute after
sternotomy

Results

Limitations

One minute after
induction, significant
decreases in MAP and
SVR one minute after
induction in Group P (p
< 0.01)

Lack of bispectral index
(BIS) monitoring

No significant changes
in HR, PAP, PCWP,
PVR, SV, LVSWI, or
RVSWI between
groups
No significant changes
in ST segment
deviation from baseline
between groups

75

Note: IV-intravenous, CABG – coronary artery bypass grafting, ASA-American Association of Anesthesiologists, LVEF-left ventricular ejection fraction,
LVEDP=left ventricular end diastolic pressure, MAP-mean arterial pressure, SVR-systemic vascular resistance, HR-heart rate, PAP-pulmonary artery pressure,
PCWP-pulmonary artery wedge pressure, PVR-pulmonary vascular resistance, SV-stroke volume, LVSWI-left ventricular stroke work index, RVSWI-right
ventricular stroke work index
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Table B-2
Pandey, A. K., Makhija, N., Chauhan, S., Das, S., Kiran, U., Bisoi, A. K., & Lakshmy, R. (2012). The effects of etomidate and
propofol induction on hemodynamic and endocrine response in patients undergoing coronary artery bypass graft surgery on
cardiopulmonary bypass. World Journal of Cardiovascular Surgery, 2(3), 48-53. https://doi.org/10.4236/wjcs.2012.2301
Research Question

Project Design

Site, Sample

Method

Results

Limitations

To compare the effects
of propofol and
etomidate induction on
hemodynamic
parameters and serum
cortisol levels in
patients with normal
left ventricular function
undergoing elective
CABG on CPB

Randomized controlled
trial of 100 consecutive
patients, with two
groups, each comprised
of 50 patients,
undergoing CABG with
CPB

Study conducted at the
Cardiothoracic Centre,
All India Institute of
Medical Sciences, New
Delhi, India

All patients received
similar weight-based
doses of morphine,
phenergan, midazolam,
fentanyl, and
rocuronium

Significantly lower
SBP (p=0.0005), DBP
(p=0.0011), SVR
(p=0.0474), SVRI
(p=0.026) five minutes
after intubation in
Group P

Small sample size,
same site, same surgical
team, only patients with
normal LV function

Group E (n=50):
Received etomidate as
IV induction agent

One hundred
consecutive patients,
ASA class II or III,
scheduled for elective
CABG

Group P (n=50):
Received propofol as
IV induction agent

All patients had
“normal LV function”.
“Normal” is not defined
Excluded: pre-existing
arrhythmias, CHF,
renal dysfunction
(creatinine > 2 mg/dl),
bleeding/coagulopathic
conditions, receiving
steroid therapy,
mechanically ventilated
preoperatively, or
undergoing an
emergency operation

Group E patients
received 0.2 mg/kg
etomidate
Group P patients
received 2.0 mg/kg
propofol
Hemodynamic
measurements taken
pre-induction, and
again five minutes postintubation
Serum cortisol levels
measured pre-induction,
after termination of
CPB, and 24 hours
post-op

Serum cortisol levels
significantly lower but
still within normal
levels (9-25 mcg/dL) at
time of weaning from
CPB. Average cortisol
reduced by nearly 50%
in Group E (p=0.0015),
increased 2.5 fold in
group P (p=0.0054)
More stable
hemodynamics in group
E than group P
(p<0.05)
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Note: IV-intravenous, CABG – coronary artery bypass grafting, CPB-cardiopulmonary bypass, ASA-American Association of Anesthesiologists, CHFcongestive heart failure, LV- left ventricular, SBP-systolic blood pressure, DBP-diastolic blood pressure pressure, SVR-systemic vascular resistance, SVRIsystemic vascular resistance index
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Table B-3
Kaushal, R. P., Vatal, A., & Pathak, R. (2015). Effect of etomidate and propofol induction on hemodynamic and endocrine response in
patients undergoing coronary artery bypass grafting/mitral valve and aortic valve replacement surgery on cardiopulmonary bypass.
Annals of Cardiac Anesthesia, 18(2), 172-178. https://doi.org/10.4103/0971-9784.154470
Purpose
To compare induction
with etomidate and
propofol in cardiac
surgeries

Project Design

Site, Sample

Method

Results

Prospective,
randomized study of 60
patients randomly
divided into two
groups, each comprised
of 30 patients,
undergoing CABG,
MVR, AVR on CPB

Study site not provided

All patients: identical
doses of glycopyrrolate,
midazolam, ranitidine,
and ondansetron, same
weight-based dose of
fentanyl

Significantly decreases
in SBP (p<0.001), DBP
(p=0.007), MAP
(p<0.001) in Group I.

Group I (n=30):
Received propofol as
IV induction agent

Excluded: pre-existing
CHF, renal dysfunction
(creatinine > 2 mg/dl),
receiving long term
steroid therapy,
mechanically ventilated
preoperatively, with
known adrenal or
endocrine dysfunction,
or undergoing an
emergency operation

Group II (n=30):
Received etomidate as
IV induction agent
Randomization
performed by opening a
sealed envelope just
before entering
operating theater

Sixty patients, ages 2060, weighing 40-70 kg,
ASA class II or III,
scheduled for elective
CABG, AVR, or MVR
on CPB

Group I: 2 mg/kg
propofol
Group II:0.2 mg/kg
etomidate
Hemodynamic
measurements taken
pre-induction, after
induction, after
intubation, and five
minutes post intubation
Serum cortisol levels
measured pre-induction,
during CPB, after
termination of CPB,
and 24 hours post-op

Significant decrease in
SVR in both groups.
Five minutes post
induction (p<0.001)
Significant decrease in
serum cortisol
(approximately 50%)
during and post CPB in
etomidate group while
almost doubling in
propofol group. Levels
returned to baseline
after 24 hours in both
groups (p<0.001)

Limitations
Not discussed
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Note: IV-intravenous, CABG – coronary artery bypass grafting, MVR-mitral valve replacement, AVR-aortic valve replacement, CPB-cardiopulmonary bypass,
ASA-American Association of Anesthesiologists, CHF-congestive heart failure, SBP-systolic blood pressure, DBP-diastolic blood pressure pressure, MAP-mean
arterial pressure, CO-cardiac output, CI-cardiac index, SVR-systemic vascular resistance

80

Table B-4
Shivanna, S., Priye, S., Jagannath, S., Kadli, C., Mayuri, M., Vikas, V., ... Reddy, D. (2015). A comparative study of haemodynamic
effects of propofol and etomidate as an induction agent in coronary artery surgery. Journal of Evolution of Medical and Dental
Sciences, 4(1), 2278-4748. https://doi.org/10.14260/jemds/2015/88
Purpose

Project Design

Site, Sample

To evaluate the
hemodynamic effects of
etomidate in
comparison to that of
propofol during
induction of general
anesthesia

Prospective,
randomized, double
blind comparative study
40 consecutive patients
randomly divided into
two groups, each
comprised of 20
patients, undergoing
CABG with CPB

Site: Vydehi Institute of
Medical Sciences and
Research Centre,
Bengaluru, India

Group P (n=20):
Received propofol as
IV induction agent
Group E (n=20):
Received etomidate as
IV induction agent

Forty consecutive adult
patients with normal
LV function, ages 3565, weighing 40-70 kg,
ASA class I or II,
scheduled for elective
CABG with CPB
Excluded: LVEF <50%,
pre-existing
arrhythmias, CHF,
coexisting cardiac
diseases,
bleeding/coagulation
abnormalities, renal
dysfunction (creatinine
> 2 mg/dl), Mallampati
3 or 4, epilepsy, allergy,
receiving long term
steroid therapy,
mechanically ventilated
preoperatively

Method

Results

All patients: identical
doses of morphine and
promethazine

HR increased to a
larger degree in group
E

Induction performed
using infusion of IV
anesthetic titrated to
BIS <50

CI decreased in both
groups in a nonstatistically significant
manner

Group P: 0.5
mg/kg/min propofol

MAP decreased in
Group P more than
Group E, however the
difference was not
statistically significant

Group II:0.05
mg/kg/min etomidate
Hemodynamic
measurements recorded
before induction, after
induction, after
intubation, and seven
minutes post induction

SVR decreased in
group P in a moderately
significant manner
(p=0.022)
After intubation, SVR
increased in both
groups, with group E
demonstrating a
statistically significant
larger increase than
group P (p=0.003)

Limitations
Not discussed

81

Note: IV-intravenous, CABG – coronary artery bypass grafting, CPB-cardiopulmonary bypass, ASA-American Association of Anesthesiologists, LV-left
ventricle, CHF-congestive heart failure, MAP-mean arterial pressure, CI-cardiac index, SVR-systemic vascular resistance
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Table B-5
Kamath, M. R., Kamath, S., & Patla, K. P. (2016). Propofol or etomidate: Does it genuinely matter for induction in cardiac
surgical procedures? Indian Journal of Clinical Anesthesia, 3(4), 551-555. https://doi.org/10.18231/2394-4994.2016.0012
Purpose

Project Design

Site, Sample

To compare propofol
with etomidate with
respect to
hemodynamic stability
during induction of
anesthesia for open
cardiac surgical
procedures

Prospective,
randomized study of 60
patients randomly
divided into two
groups, each comprised
of 30 patients,
undergoing elective
cardiac surgical
procedures

Site: Not provided.
Authors are affiliated
with KS Hegde Medical
Academy, Mangalore,
India

All patients:
premedicated orally
with 50 mg ranitidine
and 10 mg diazepam
night before surgery

Sixty adult patients,
ages 20-60

Received fentanyl 5
mcg/kg and midazolam
0.05 mg/kg preinduction

Excluded: Not provided
Group A (n=30):
Received propofol as
IV induction agent
Group B (n=30):
Received etomidate as
IV induction agent
Randomization
performed using closed
envelope technique

Method

Group A: 1.5 mg/kg
propofol
Group B: 0.2 mg/kg
etomidate
Hemodynamic
measurements recorded
before induction, after
induction, after
intubation, and five
minutes post induction

Results
Propofol group:
After induction:
Statistically significant
decrease in SBP, MAP,
CO and CI (p<0.05)
After intubation:
Statistically significant
increase in DBP, CO
and CI (p<0.05)
Five minutes after
intubation:
Statistically significant
increase in MAP, CVP,
and PCWP in propofol
(p<0.05)
No significant changes
in any other parameters
at these times
Etomidate group:
No significant changes
at any time

Limitations
Not discussed
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Note: IV-intravenous, SBP-systolic blood pressure, DBP-diastolic blood pressure, MAP-mean arterial pressure, CO-cardiac output, CI-cardiac index, SVRsystemic vascular resistance, PCWP-pulmonary capillary wedge pressure
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Table B-6
Soleimani, A., Heidari, N., Habibi, M. R., Kiabi, F. H., Khademloo, M., Zeydi, A. E., & Sohrabi, F. B. (2017). Comparing
hemodynamic responses to diazepam, propofol and etomidate during anesthesia induction in patients with left ventricular dysfunction
undergoing coronary artery bypass graft surgery: A double-blind, randomized clinical trial. Medical Archives, 71(3), 198-203.
https://doi.org/10.5455/medarh.2017.71.198-203
Purpose

Project Design

Site, Sample

Method

Results

Limitations

To compare the
hemodynamic
responses to propofol,
etomidate and diazepam
following anesthesia
induction, laryngoscopy
and intubation in
CABG surgery patients
with low ejection
fraction (EF)

Double-blind
randomized clinical
study of 150 patients
scheduled for elective
CABG with CPB,
randomly allocated into
three groups of 50

Site: Cardiac surgery
unit and open heart
intensive care unit of a
teaching hospital
affiliated with
Mazandaran University
of Medical Sciences,
Sari, Iran

All patients:
Premedicated with 2
mcg/kg fentanyl and
0.03 mcg/kg midazolam

Statistically significant
decrease in SBP, DBP
and MAP in all three
groups one minute after
induction (p<0.001).
Decrease remained for
other measurements in
propofol group
(p<0.001), with
recovery to near
baseline in other groups

Dosages per kilogram
of body weight may be
unequally distributed
between groups, and be
a confounding variable

Group A: Received
propofol as IV
induction agent
Group B: Received
etomidate as IV
induction agent
Group C: Received
diazepam as IV
induction agent
Randomization
performed using closed
envelope technique

150 adult patients with
CAD and left
ventricular dysfunction
(EF ≤ 35%), and stable
hemodynamics
Excluded: Patients with
history of chronic
inflammatory disease,
endocarditis, adrenal
insufficiency, sepsis,
steroid use within 6
months, difficult
intubation, combined
CABG/other surgery

1.5 mg/kg
succinylcholine after
induction to facilitate
intubation
Group A (n=50):
1.5 mg/kg propofol
Group B (n=50):
0.2 mg/kg etomidate
Group C (n=50):
0.3 mg/kg diazepam
Hemodynamic
measurements recorded
before induction, before
larygoscopy, one and
five minutes post
induction

A statistically
significant percentage
of patients in the
propofol group required
rescue administration of
ephedrine compared
with the other groups
(p<0.001).
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Note: IV-intravenous, CAD-coronary artery disease, EF=ejection fraction, SBP-systolic blood pressure, DBP-diastolic blood pressure, MAP-mean arterial
pressure, HR-heart rate
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Table B-7
Mala, R., & Narmada, S. (2017). Prospective randomised study comparing the haemodynamic and endocrine response to induction
with etomidate and propofol in patients undergoing cardiac surgery on cardiopulmonary bypass. Indian Journal of Applied Research,
7(10), 145-146. Retrieved from https://www.worldwidejournals.com/indian-journal-of-applied-research
(IJAR)/fileview/October_2017_1506777489__54.pdf
Purpose

Project Design

To compare the
hemodynamic profile
and the hormonal
alteration between
etomidate and propofol
following induction in
cardiac surgery,
particularly in patients
undergoing coronary
artery bypass surgery
on cardiopulmonary
bypass

Prospective randomized
study of 30 patients
scheduled for elective
CABG with CPB,
randomly allocated into
two groups of 15
Propofol Group (n=15):
Received 2 mg/kg
propofol as IV
induction agent
Etomidate Group
(n=15): Received 0.2
mg/kg etomidate as IV
induction agent
Randomization
performed using closed
envelope technique

Site, Sample
Site: Not Provided
Sample:
30 adult patients (ages
18-60), ASA II and III,
Mallampati I and II,
with normal LV
function
Excluded: History of
LV dysfunction,
arrhythmia, CHF, preop mechanical
ventilation, current
steroid therapy, existing
bleeding
disorder/coagulopathy,
renal dysfunction
(creatinine > 2.0
mg.dL), difficult
airway, poor lung
compliance, any other
comorbidities except
diabetes or
hypertension

Method

Results

Limitations

Hemodynamic
measurements recorded
before induction, at
one, two and three
minutes after induction,
and at 1 and five
minutes after intubation

Statistically significant
decrease in SBP from
baseline after induction,
much lower 5 minutes
after intubation in the
propofol group
(p<0.05)

Dosages per kilogram
of body weight may be
unequally distributed
between groups, and be
a confounding variable

Statistically significant
decrease in CI from
baseline, two, and three
minutes following
induction in the
propofol group
(p<0.05)
Serum cortisol 50% of
baseline at initiation of
CPB in etomidate
group, almost double
baseline in propofol
group (p<0.05)
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Note: IV-intravenous, CAD-coronary artery disease, EF=ejection fraction, SBP-systolic blood pressure, DBP-diastolic blood pressure, MAP-mean arterial
pressure, HR-heart rate
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Table B-8
Meena, R., Sharma, R. S., Ranawat, P., Saiyed, A., & Verma, I. (2017). Comparison of hemodynamic and serum cortisol levels in
response to anesthetic induction with etomidate or propofol in patients undergoing CABG surgery. Indian Journal of Clinical
Anaesthesia, 4(3), 345-351. https://doi.org/10.18231/2394-4994.2017.0071
Purpose

Project Design

Site, Sample

To compare the effects
of induction agents
etomidate and propofol
on hemodynamic and
serum cortisol levels in
patients undergoing
coronary artery bypass
graft surgery on
cardiopulmonary
bypass

Prospective randomized
study of 60 patients
scheduled for elective
CABG with CPB,
randomly allocated into
two groups of 15

Site: Department of
Anesthesiology, S.M.S.
hospital and attached
group of hospitals,
Jaipur, Rajasthan, India

Group A (n=30):
Received etomidate 0.3
mg/kg as IV induction
agent
Group B (n=30):
Received propofol 2.0
mg/kg as IV induction
agent
Randomization
performed by “chit in
the box” method

Sample:
60 adult patients (ages
25-60), ASA II and III,
with triple vessel
disease and LVEF
<45%, presenting for
elective CABG
Excluded: Patients with
decompensated heart
failure, renal
dysfunction, bleeding
and coagulation
abnormalities, preexisting arrhythmias, on
mechanical ventilation,
on steroid therapy,
undergoing emergency
procedure

Method
All patients:
NPO x eight hours
Morphine 0.1 mg/kg IM
and promethazine 0.5
mg /kg IM 30 minutes
prior to induction
Fentanyl 4 mcg/kg, then
baseline parameters
(HR, SBP, DBP, MAP,
CVP, PCWP, CO, CI,
SVR, SVRI, PVR,
PVRI) were recorded
over ten minutes with
pre-oxygenation, after
which induction was
performed.
Hemodynamic
measurements and
cortisol level recorded 2
minutes after induction
and after intubation.

Results
Cortisol level:
Group A: significant
decrease (up to 60%)
from baseline coming
off bypass (p=0.0036),
significant increase
from baseline 24 hours
post op
Group B: Large, but
statistically
insignificant increase
(up to double) coming
off bypass, also
significant increase 24
hours post op
Hemodynamics:
Significant decrease in
SBP (p=0.0007), DBP
(p=0.0371), SVR
(p=0.0369), SVRI
(p=0.0120) after
induction in group B
Large, but statistically
insignificant increase in

Limitations
Small sample size

89
HR and SBP after
intubation in group A

Note: CABG-coronary artery bypass graft, CPB-cardiopulmonary bypass, IV-intravenous, , ASA-American Society of Anesthesiologists, LVEF-left ventricular
ejection fraction, NPO-nothing per os, IM-intramuscular, HR-heart rate, SBP-systolic blood pressure, DBP-diastolic blood pressure, MAP-mean arterial pressure,
CVP-central venous pressure, PCWP-pulmonary capillary wedge pressure, CO-cardiac output, CI-cardiac index, SVR-systemic vascular resistance, SVRIsystemic vascular resistance index, PVR-pulmonary vascular resistance, PVRI-pulmonary vascular resistance index
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Table B-9
Hannam, J. A., Mitchell, S. J., Cumin, D., Frampton, C., Merry, A. F., Moore, M. R., & Kruger, C. J. (2019). Haemodynamic profiles
of etomidate vs propofol for induction of anaesthesia: A randomised controlled trial in patients undergoing cardiac surgery. British
Journal of Anaesthesia, 122(2), 198-205. https://doi.org/10.1016/j.bja.2018.09.027
Purpose

Project Design

Site, Sample

Method

To test the hypothesis
that etomidate is
superior to propofol for
induction of anesthesia
in relation to
hemodynamic stability
over the first 10
minutes after induction,
in patients undergoing
cardiac surgery

Randomized, controlled
superiority trial with
open-label (unblended)
and blinded phases.

Site: Green Lane
Cardiothoracic Surgery
Unit, Auckland, New
Zealand

Phase I (n=76): open
label – anesthetist not
blinded

Sample:
150 adult patients (ages
18-60), ASA II-IV,
undergoing elective
CABG, valve surgery,
combination
CABG/valve surgery,
and thoracic aorta
surgery

Patients were premedicated with
midazolam and fentanyl
at the anesthetists’
discretion, with nonstandardized doses
chosen by the
anesthetist. Induction
was accomplished with
titration of the allocated
medication to loss of
responsiveness to
verbal stimuli. The
remainder of the
anesthetic appeared to
be standardized.

•
•

Propofol
Group (n=40):
Etomidate
Group (n=36)

Phase II (n=74): closedlabel – all clinical staff
blinded
•
•

Propofol
Group (n=35):
Etomidate
Group (n=39)

Excluded: Documented
allergy to propofol or
etomidate, scheduled
for transplant

MAP recorded every 30
seconds. Primary
endpoint was area
under the baseline MAP
over the first 10
minutes after induction

Results
34% greater reduction
in MAP with propofol
than with etomidate
(p=0.009).

Limitations
Unequal numbers of
study subjects between
phases and between
anesthetics within each
phase
Lack of standardized
protocol aside from the
study intervention
could introduce
confounding factors
related to anesthesia
provider decisionmaking and practice
that affect results
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Note: ASA-American Society of Anesthesiologists, CABG-coronary artery bypass graft, MAP-mean arterial pressure
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Appendix C
Table C-1
Basagan-Mogol, E., Goren, S., Korfali, G., Turker, G., & Kaya, F. N. (2010). Induction of anesthesia in coronary artery bypass graft
surgery: The hemodynamic and analgesic effects of ketamine. Clinics, 65(2), 133-138. https://doi.org/10.1590/S1807
59322010000200003
Propofol

Etomidate

Ketamine

Heart Rate

0

0

Systolic Blood Pressure

NR

NR

Diastolic Blood Pressure

NR

NR

Mean Arterial Pressure

↓

0

Cardiac Output

0

0

Cardiac Index

0

0

SVR

↓

0

Endocrine Response

NR

NR

Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify
that the particular medication was not included in the study
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Table C-2
Pandey, A. K., Makhija, N., Chauhan, S., Das, S., Kiran, U., Bisoi, A. K., & Lakshmy, R. (2012). The effects of etomidate and
propofol induction on hemodynamic and endocrine response in patients undergoing coronary artery bypass graft surgery on
cardiopulmonary bypass. World Journal of Cardiovascular Surgery, 2(3), 48-53. https://doi.org/10.4236/wjcs.2012.2301
Propofol

Etomidate

Heart Rate

0

0

Systolic Blood Pressure

↓

0

Diastolic Blood Pressure

↓

0

Mean Arterial Pressure

NR

NR

Cardiac Output

0

0

Cardiac Index

0

0

SVR

↓

0

Endocrine Response

↑

↓

Ketamine

Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify
that the particular medication was not included in the study
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Table C-3
Kaushal, R. P., Vatal, A., & Pathak, R. (2015). Effect of etomidate and propofol induction on hemodynamic and endocrine response in
patients undergoing coronary artery bypass grafting/mitral valve and aortic valve replacement surgery on cardiopulmonary bypass.
Annals of Cardiac Anesthesia, 18(2), 172-178. https://doi.org/10.4103/0971-9784.154470
Propofol

Etomidate

Heart Rate

0

0

Systolic Blood Pressure

↓

0

Diastolic Blood Pressure

↓

0

Mean Arterial Pressure

↓

0

Cardiac Output

↓

0

Cardiac Index

↓

0

SVR

↓

0

Endocrine Response

↑

↓

Ketamine

Note: Arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify that the particular
medication was not included in the study
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Table C-4
Shivanna, S., Priye, S., Jagannath, S., Kadli, C., Mayuri, M., Vikas, V., ... Reddy, D. (2015). A comparative study of haemodynamic
effects of propofol and etomidate as an induction agent in coronary artery surgery. Journal of Evolution of Medical and Dental
Sciences, 4(1), 2278-4748. https://doi.org/10.14260/jemds/2015/88
Propofol

Etomidate

Heart Rate

0

0

Systolic Blood Pressure

NR

NR

Diastolic Blood Pressure

NR

NR

Mean Arterial Pressure

↓

↓

Cardiac Output

NR

NR

Cardiac Index

0

0

SVR

↓

↑ (post intubation)

Endocrine Response

NR

NR

Ketamine

Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify
that the particular medication was not included in the study
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Table C-5
Kamath, M. R., Kamath, S., & Patla, K. P. (2016). Propofol or etomidate: Does it genuinely matter for induction in cardiac
surgical procedures? Indian Journal of Clinical Anesthesia, 3(4), 551-555. https://doi.org/10.18231/2394-4994.2016.0012
Propofol

Etomidate

Heart Rate

0

0

Systolic Blood Pressure

↓

0

Diastolic Blood Pressure

0

0

Mean Arterial Pressure

↓

0

Cardiac Output

↓

0

Cardiac Index

↓

0

SVR

0

0

Endocrine Response

NR

NR

Ketamine

Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify
that the particular medication was not included in the study
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Table C-6
Soleimani, A., Heidari, N., Habibi, M. R., Kiabi, F. H., Khademloo, M., Zeydi, A. E., & Sohrabi, F. B. (2017). Comparing
hemodynamic responses to diazepam, propofol and etomidate during anesthesia induction in patients with left ventricular dysfunction
undergoing coronary artery bypass graft surgery: A double-blind, randomized clinical trial. Medical Archives, 71(3), 198-203.
https://doi.org/10.5455/medarh.2017.71.198-203
Propofol

Etomidate

Heart Rate

↓

↓

Systolic Blood Pressure

↓

0

Diastolic Blood Pressure

↓

0

Mean Arterial Pressure

↓

0

Cardiac Output

NR

NR

Cardiac Index

NR

NR

SVR

NR

NR

Endocrine Response

NR

NR

Ketamine

Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify
that the particular medication was not included in the study
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Table C-7
Mala, R., & Narmada, S. (2017). Prospective randomised study comparing the haemodynamic and endocrine response to induction
with etomidate and propofol in patients undergoing cardiac surgery on cardiopulmonary bypass. Indian Journal of Applied Research,
7(10), 145-146. Retrieved from https://www.worldwidejournals.com/indian-journal-of-applied-research
(IJAR)/fileview/October_2017_1506777489__54.pdf
Propofol

Etomidate

Heart Rate

↓

↓

Systolic Blood Pressure

↓

0

Diastolic Blood Pressure

0

0

Mean Arterial Pressure

↓

0

Cardiac Output

NR

NR

Cardiac Index

↓

0

SVR

NR

NR

Endocrine Response

↑

↓

Ketamine

Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify
that the particular medication was not included in the study
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Table C-8
Meena, R., Sharma, R. S., Ranawat, P., Saiyed, A., & Verma, I. (2017). Comparison of hemodynamic and serum cortisol levels in
response to anesthetic induction with etomidate or propofol in patients undergoing CABG surgery. Indian Journal of Clinical
Anaesthesia, 4(3), 345-351. https://doi.org/10.18231/2394-4994.2017.0071
Propofol

Etomidate

Heart Rate

↓

↓

Systolic Blood Pressure

↓

0

Diastolic Blood Pressure

↓

0

Mean Arterial Pressure

↓

0

Cardiac Output

0

0

Cardiac Index

0

0

SVR

↓

0

Endocrine Response

↑

↓

Ketamine

Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify
that the particular medication was not included in the study
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Table C-9
Hannam, J. A., Mitchell, S. J., Cumin, D., Frampton, C., Merry, A. F., Moore, M. R., & Kruger, C. J. (2019). Haemodynamic profiles
of etomidate vs propofol for induction of anaesthesia: A randomised controlled trial in patients undergoing cardiac surgery. British
Journal of Anaesthesia, 122(2), 198-205. https://doi.org/10.1016/j.bja.2018.09.027
Propofol

Etomidate

Heart Rate

NR

NR

Systolic Blood Pressure

NR

NR

Diastolic Blood Pressure

NR

NR

Mean Arterial Pressure

↓

0

Cardiac Output

NR

NR

Cardiac Index

NR

NR

SVR

NR

NR

Endocrine Response

NR

NR

Ketamine

Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify
that the particular medication was not included in the study
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Appendix D
Table D-1
Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist
Basagan-Mogol, E., Goren, S., Korfali, G., Turker, G., & Kaya, F. N. (2010). Induction
of anesthesia in coronary artery bypass graft surgery: The hemodynamic and analgesic
effects of ketamine. Clinics, 65(2), 133-138.
https://doi.org/10.1590/S180759322010000200003
D) Are the results of the trial valid?
YES
12. Did the trial address a clearly focused
X
issue?
13. Was the assignment of patients to
X
treatments randomized?
14. Were all of the patients who entered
the trial properly accounted for at its
X
conclusion?
15. Were patients, health workers, and
study personnel “blind” to treatment?
16. Were the groups similar at the start of
X
the trial?
17. Aside from the experimental
intervention, were groups treated
X
equally?
E) What are the results?
18. How large was the treatment effect?
Not discussed
19. How precise was the estimate of the
Not discussed
treatment effect?
F) Will the results help locally?
YES
20. Can the results be applied in your
X
context? (or to the local population?)
21. Were all clinically important outcomes
X
considered?
22. Are the benefits worth the harms?
X

CAN’T TELL

NO

X

CAN’T TELL

NO
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Table D-2
Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist
Pandey, A. K., Makhija, N., Chauhan, S., Das, S., Kiran, U., Bisoi, A. K., & Lakshmy, R.
(2012). The effects of etomidate and propofol induction on hemodynamic and endocrine
response in patients undergoing coronary artery bypass graft surgery on cardiopulmonary
bypass. World Journal of Cardiovascular Surgery, 2(3), 48-53.
https://doi.org/10.4236/wjcs.2012.23011

A) Are the results of the trial valid?
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were groups treated
equally?
B) What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C) Will the results help locally?
9. Can the results be applied in your
context? (or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms?

YES

CAN’T TELL

NO

X
X
X
X
X
X
Not discussed
Not discussed
YES
X
X
X

CAN’T TELL

NO
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Table D-3
Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist
Kaushal, R. P., Vatal, A., & Pathak, R. (2015). Effect of etomidate and propofol induction on
hemodynamic and endocrine response in patients undergoing coronary artery bypass
grafting/mitral valve and aortic valve replacement surgery on cardiopulmonary bypass. Annals of
Cardiac Anesthesia, 18(2), 172-178. https://doi.org/10.4103/0971-9784.154470

A) Are the results of the trial valid?
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were groups treated
equally?
B) What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C) Will the results help locally?
9. Can the results be applied in your
context? (or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms?

YES

CAN’T TELL

NO

X
X
X
X
X
X
Not discussed
Not discussed
YES
X
X
X

CAN’T TELL

NO
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Table D-4
Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist
Shivanna, S., Priye, S., Jagannath, S., Kadli, C., Mayuri, M., Vikas, V., ... Reddy, D.
(2015). A comparative study of haemodynamic effects of propofol and etomidate as an
induction agent in coronary artery surgery. Journal of Evolution of Medical and Dental
Sciences, 4(1), 2278-4748. https://doi.org/10.14260/jemds/2015/88
A) Are the results of the trial valid?
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were groups treated
equally?
B) What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C) Will the results help locally?
9. Can the results be applied in your
context? (or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms?

YES

CAN’T TELL

NO

X
X
X
X
X
X
Not discussed
Not discussed
YES
X
X
X

CAN’T TELL

NO
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Table D-5
Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist
Kamath, M. R., Kamath, S., & Patla, K. P. (2016). Propofol or etomidate: Does it
genuinely matter for induction in cardiac surgical procedures? Indian Journal of Clinical
Anesthesia, 3(4), 551-555. https://doi.org/10.18231/2394-4994.2016.0012
A) Are the results of the trial valid?
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were groups treated
equally?
B) What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C) Will the results help locally?
9. Can the results be applied in your
context? (or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms?

YES

CAN’T TELL

NO

X
X
X
X
X
X
Not discussed
Not discussed
YES
X
X
X

CAN’T TELL

NO
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Table D-6
Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist
Soleimani, A., Heidari, N., Habibi, M. R., Kiabi, F. H., Khademloo, M., Zeydi, A. E., &
Sohrabi, F. B. (2017). Comparing hemodynamic responses to diazepam, propofol and
etomidate during anesthesia induction in patients with left ventricular dysfunction
undergoing coronary artery bypass graft surgery: A double-blind, randomized clinical
trial. Medical Archives, 71(3), 198-203. https://doi.org/10.5455/medarh.2017.71.198-203
A) Are the results of the trial valid?
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were groups treated
equally?
B) What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C) Will the results help locally?
9. Can the results be applied in your
context? (or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms?

YES

CAN’T TELL

NO

X
X
X
X
X
X
Not discussed
Not discussed
YES
X
X
X

CAN’T TELL

NO

107

Table D-7
Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist
Mala, R., & Narmada, S. (2017). Prospective randomised study comparing the
Haemodynamic and endocrine response to induction with etomidate and propofol in
patients undergoing cardiac surgery on cardiopulmonary bypass. Indian Journal of
Applied Research, 7(10), 145-146. Retrieved from
https://www.worldwidejournals.com/indian-journal-of-applied-research
(IJAR)/fileview/October_2017_1506777489__54.pdf
A) Are the results of the trial valid?
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were groups treated
equally?
B) What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C) Will the results help locally?
9. Can the results be applied in your
context? (or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms?

YES

CAN’T TELL

NO

X
X
X
X
X
X
Not discussed
Not discussed
YES
X
X
X

CAN’T TELL

NO
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Table D-8
Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist
Meena, R., Sharma, R. S., Ranawat, P., Saiyed, A., & Verma, I. (2017). Comparison of
hemodynamic and serum cortisol levels in response to anesthetic induction with
etomidate or propofol in patients undergoing CABG surgery. Indian Journal of Clinical
Anaesthesia, 4(3), 345-351. https://doi.org/10.18231/2394-4994.2017.0071
A) Are the results of the trial valid?
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were groups treated
equally?
B) What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C) Will the results help locally?
9. Can the results be applied in your
context? (or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms?

YES

CAN’T TELL

NO

X
X
X
X
X
X
Not discussed
Not discussed
YES
X
X
X

CAN’T TELL

NO
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Table D-9
Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist
Hannam, J. A., Mitchell, S. J., Cumin, D., Frampton, C., Merry, A. F., Moore, M. R., &
Kruger, C. J. (2019). Haemodynamic profiles of etomidate vs propofol for induction of
anaesthesia: A randomised controlled trial in patients undergoing cardiac surgery. British
Journal of Anaesthesia, 122(2), 198-205. https://doi.org/10.1016/j.bja.2018.09.027
A) Are the results of the trial valid?
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were groups treated
equally?
B) What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C) Will the results help locally?
9. Can the results be applied in your
context? (or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms?

YES

CAN’T TELL

NO

X
X
X
X
X
X
Not discussed
Not discussed
YES

CAN’T TELL

X
X
X

Note: This study was performed in two phases. The patient was blinded during both
phases. Phase I was open-label for the anesthesia provider. In phase II, the anesthesia
provider was blinded to the treatment.

NO
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Appendix E
Cross-Study Analysis
AUTHOR / YEAR
Study 1
(Basagan-Mogol et al.,
2010)

MEDICATION PROTOCOL
Group K: ketamine 2.0 mg/kg

Study 2
(Pandey et al., 2012)

Group E: etomidate 0.2 mg/kg

RESULTS
Decreased MAP and SVR in group P one minute after induction

Group P: propofol 0.5 mg/kg
Decreased SBP, DBP, SVR, SVRI in group P five minutes after
intubation

Group p: propofol 2.0 mg/kg
More stable hemodynamics group E
Decreased cortisol levels in group E at weaning from CPB
Study 3
(Kaushal et al., 2015)

Group I: propofol 2.0 mg/kg

Increased cortisol levels in group P at weaning from CPB
Decreased SBP, DBP, MAP in group I

Group II: etomidate 0.2 mg/kg

Decreased SVR in both groups five minutes post induction
Decreased cortisol level group II during/post CPB

Study 4
(Shivanna et al., 2015)

Group P: propofol 0.5
mg/kg/min
Group E: etomidate 0.05
mg/kg/min

Increased cortisol level group I during/post CPB
Decreased SBP, MAP, CO and CI in group P after induction
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Study 5
(Kamath et al., 2016)

Study 6
(Soleimani et al., 2017)

Group A: propofol 1.5 mg/kg

Decreased SBP, MAP, CO and CI in group A after induction

Group B: etomidate 0.2 mg/kg

Increased DBP, CO, CI in group A after intubation

Group A: propofol 1.5 mg/kg

Increased MAP, CVP, PCWP in group A five minutes after
intubation
Decreased SBP, DBP, MAP in all groups one minute after
induction, remaining low longer in group A

Group B: etomidate 0.2 mg/kg
Study 7
(Mala & Narmala, 2017)

Study 8
(Meena et al., 2017)

Study 9
(Hannam et al., 2019)

Group C: diazepam 0.3 mg/kg
Propofol group: propofol 2.0
mg/kg

Larger number of patients in group A required rescue ephedrine
administration
Decrease in SBP in propofol group after induction, much lower
five minutes after induction

Etomidate group: etomidate 0.2
mg/kg

Decrease in CI two minutes and three minutes after induction in
propofol group

Group A: etomidate 0.3 mg/kg

50% reduction in cortisol in etomidate group, nearly twofold
increase in cortisol in propofol group
Decreased cortisol group A, increased cortisol group B

Group B: propofol 2.0 mg/kg

Decreased SBP, DBP, SVR, SVRI after induction group B

Propofol group: propofol titrated
at anesthetist’s discretion to
achieve loss of response to
verbal command
Etomidate group: etomidate
titrated at anesthetist’s discretion

Increased HR, SBP after intubation group A
34% greater reduction in MAP with propofol
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to achieve loss of response to
verbal command

